Novel genomic loci influence patterns of structural covariance in the human

brain

1 2

3

18

- 4 Junhao Wen^{1,2*}, Ilya M. Nasrallah^{2,3}, Ahmed Abdulkadir², Theodore D. Satterthwaite^{2,4}, Zhijian Yang²,
- 5 Guray Erus², Timothy Robert-Fitzgerald⁵, Ashish Singh², Aristeidis Sotiras⁶, Aleix Boquet-Puiadas⁷,
- Elizabeth Mamourian², Jimit Doshi², Yuhan Cui², Dhivya Srinivasan², Ioanna Skampardoni², Jiong 6
- 7 Chen², Gyujoon Hwang², Mark Bergman², Jingxuan Bao⁸, Yogasudha Veturi⁹, Zhen Zhou², Shu Yang⁸,
- Paola Dazzan¹⁰, Rene S. Kahn¹¹, Hugo G. Schnack¹², Marcus V. Zanetti¹³, Eva Meisenzahl¹⁴, Geraldo F. 8
- Busatto¹³, Benedicto Crespo-Facorro¹⁵, Christos Pantelis¹⁶, Stephen J. Wood¹⁷, Chuanjun Zhuo¹⁸, Russell 9
- T. Shinohara^{2,5}, Ruben C. Gur⁴, Raquel E. Gur⁴, Nikolaos Koutsouleris¹⁹, Daniel H. Wolf^{2,4}, Andrew J. 10
- Saykin²⁰, Marylyn D. Ritchie⁹, Li Shen⁸, Paul M. Thompson²¹, Olivier Colliot²², Katharina Wittfeld²³, 11
- Hans J. Grabe²³, Duygu Tosun²⁴, Murat Bilgel²⁵, Yang An²⁵, Daniel S. Marcus²⁶, Pamela LaMontagne²⁶, 12
- Susan R. Heckbert²⁷, Thomas R. Austin²⁷, Lenore J. Launer²⁸, Mark Espeland²⁹, Colin L Masters³⁰, Paul 13
- Maruff³⁰, Jurgen Fripp³¹, Sterling C. Johnson³², John C. Morris³³, Marilyn S. Albert³⁴, R. Nick Bryan³, 14
- Susan M. Resnick²⁵, Yong Fan², Mohamad Habes³⁵, David Wolk^{2,36}, Haochang Shou^{2,5}, and Christos 15
- Davatzikos^{2*}, for the iSTAGING, the BLSA, the BIOCARD, the PHENOM, the ADNI studies, and the 16
- 17 AI4AD consortium
- 19 ¹Laboratory of AI and Biomedical Science (LABS), Stevens Neuroimaging and Informatics Institute, Keck School of
- 20 Medicine of USC, University of Southern California, Los Angeles, California, USA.
- 21 ²Artificial Intelligence in Biomedical Imaging Laboratory (AIBIL), Center for Biomedical Image Computing and
- 22 23 Analytics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
- ³Department of Radiology, University of Pennsylvania, Philadelphia, USA.
- 24 ⁴Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
- 25 ⁵Penn Statistics in Imaging and Visualization Center, Department of Biostatistics, Epidemiology, and Informatics,
- 26 Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
- 27 ⁶Department of Radiology and Institute for Informatics, Washington University School of Medicine, St. Louis, USA
- 28 ⁷Biomedical Imaging Group, EPFL, Lausanne, Switzerland
- 29 ⁸Department of Biostatistics, Epidemiology and Informatics University of Pennsylvania Perelman School of Medicine,
- 30 Philadelphia, USA
- 31 ⁹Department of Genetics and Institute for Biomedical Informatics, Perelman School of Medicine, University of
- 32 33 Pennsylvania, Philadelphia, PA, USA
- ¹⁰Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College
- 34 London, London, UK
- 35 ¹¹Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, USA
- 36 ¹²Department of Psychiatry, University Medical Center Utrecht, Utrecht, Netherlands
- 37 ¹³Institute of Psychiatry, Faculty of Medicine, University of São Paulo, São Paulo, Brazil
- 38 ¹⁴ Department of Psychiatry and Psychotherapy, HHU Düsseldorf, Germany
- 39 ¹⁵Hospital Universitario Virgen del Rocio, University of Sevilla-IBIS; IDIVAL-CIBERSAM, Sevilla, Spain
- 40 ¹⁶Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health,
- 41 Carlton South, Australia
- 42 ¹⁷Orygen and the Centre for Youth Mental Health, University of Melbourne; and the School of Psychology,
- 43 University of Birmingham, UK
- 44 ¹⁸key Laboratory of Real Tine Tracing of Brain Circuits in Psychiatry and Neurology (RTBCPN-Lab), Nankai
- 45 University Affiliated Tianjin Fourth Center Hospital; Department of Psychiatry, Tianjin Medical University, Tianjin,
- 46
- 47 ¹⁹Department of Psychiatry and Psychotherapy, Ludwig-Maximilian University, Munich, Germany
- 48 ²⁰Radiology and Imaging Sciences, Center for Neuroimaging, Department of Radiology and Imaging Sciences,
- 49 Indiana Alzheimer's Disease Research Center and the Melvin and Bren Simon Cancer Center, Indiana University
- 50 School of Medicine, Indianapolis
- 51 ²¹Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of
- 52 Medicine of USC, University of Southern California, Marina del Rey, California

- 53 ²²Sorbonne Université, Institut du Cerveau Paris Brain Institute ICM, CNRS, Inria, Inserm, AP-HP, Hôpital de la
- 54 Pitié Salpêtrière, F-75013, Paris, France
- 55 ²³Department of Psychiatry and Psychotherapy, German Center for Neurodegenerative Diseases (DZNE), University
- Medicine Greifswald, Germany
- 57 ²⁴Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA
- 58 ²⁵Laboratory of Behavioral Neuroscience, National Institute on Aging, NIH, USA
- 59 ²⁶Department of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA
- 60 ²⁷Cardiovascular Health Research Unit and Department of Epidemiology, University of Washington, Seattle, WA, 61 USA
- 62 ²⁸Neuroepidemiology Section, Intramural Research Program, National Institute on Aging, Bethesda, Maryland, USA
- 63 ²⁹Sticht Center for Healthy Aging and Alzheimer's Prevention, Wake Forest School of Medicine, Winston-Salem,
 64 North Carolina, USA
- 65 ³⁰Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
- 66 31CSIRO Health and Biosecurity, Australian e-Health Research Centre CSIRO, Brisbane, Queensland, Australia
- 67 ³²Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
- 69 ³³Knight Alzheimer Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA
- 70 ³⁴Department of Neurology, Johns Hopkins University School of Medicine, USA
- 35Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at
 San Antonio, San Antonio, USA
- 73 ³⁶Department of Neurology and Penn Memory Center, University of Pennsylvania, Philadelphia, USA
- 75 *Corresponding authors:

80

- 76 Junhao Wen, Ph.D. junhaowe@usc.edu
- 77 2025 Zonal Ave, Los Angeles, CA 90033, United States
- 78 Christos Davatzikos, Ph.D. Christos. Davatzikos @pennmedicine.upenn.edu
- 79 3700 Hamilton Walk, 7th Floor, Philadelphia, PA 19104, United States
- 81 Word counts: 5002 words

Abstract

Normal and pathologic neurobiological processes influence brain morphology in coordinated ways that give rise to patterns of structural covariance (PSC) across brain regions and individuals during brain aging and diseases. The genetic underpinnings of these patterns remain largely unknown. We apply a stochastic multivariate factorization method to a diverse population of 50,699 individuals (12 studies, 130 sites) and derive data-driven, multi-scale PSCs of regional brain size. PSCs were significantly correlated with 915 genomic loci in the discovery set, 617 of which are novel, and 72% were independently replicated. Key pathways influencing PSCs involve reelin signaling, apoptosis, neurogenesis, and appendage development, while pathways of breast cancer indicate potential interplays between brain metastasis and PSCs associated with neurodegeneration and dementia. Using support vector machines, multi-scale PSCs effectively derive imaging signatures of several brain diseases. Our results elucidate new genetic and biological underpinnings that influence structural covariance patterns in the human brain.

Significance statement

The coordinated patterns of changes in the human brain throughout life, driven by brain development, aging, and diseases, remain largely unexplored regarding their underlying genetic determinants. This study delineates 2003 multi-scale patterns of structural covariance (PSCs) and identifies 617 novel genomic loci, with the mapped genes enriched in biological pathways implicated in reelin signaling, apoptosis, neurogenesis, and appendage development. Overall, the 2003 PSCs provide new genetic insights into understanding human brain morphological changes and demonstrate great potential in predicting various neurologic conditions.

Introduction

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

Brain structure and function are interrelated via complex networks that operate at multiple scales, ranging from cellular and synaptic processes, such as neural migration, synapse formation, and axon development, to local and broadly connected circuits. Due to a fundamental relationship between activity and structure, many normal and pathologic neurobiological processes, driven by genetic and environmental factors, collectively cause coordinated changes in brain morphology. Structural covariance analyses investigate such coordinated changes by seeking patterns of structural covariation (PSC) across brain regions and individuals. For example, during adolescence, PSCs derived from magnetic resonance imaging (MRI) have been considered to reflect a coordinated cortical remodeling as the brain establishes mature networks of functional specialization.² Structural covariance is not only related to normal brain development or aging processes but can also reflect coordinated brain change due to disease. For example, individuals with motor speech dysfunction may develop brain atrophy in Broca's inferior frontal cortex and co-occurring brain atrophy in Wernicke's area of the superior temporal cortex.³ Refer to Fig. 1C for an illustrative depiction. The human brain develops, matures, and degenerates in coordinated patterns of structural covariance at the macrostructural level of brain morphology. However, the mechanisms underlying structural covariance are still unclear, and their genetic underpinnings are largely unknown. We hypothesized that brain morphology was driven by multiple genes (i.e., polygenic) collectively operating on different brain areas (i.e., pleiotropic), resulting in connected networks covaried by normal aging and various disease-related processes. Along the causal pathway from underlying genetics to brain morphological changes, we sought to elucidate which genetic underpinnings (e.g., genes), biological processes (e.g., neurogenesis), cellular components (e.g.,

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

nuclear membrane), molecular functions (e.g., nucleic acid binding), and neuropathological processes (e.g., Alzheimer's disease) might influence the formation, development, and changes of structural covariance patterns in the human brain. Previous neuroimaging genome-wide association studies (GWAS)^{4,5} have partially investigated the abovementioned questions and expanded our understanding of the genetic architecture of the human brain. However, they focused on conventional neuroanatomical regions of interest (ROI) instead of data-driven PSCs. In brain imaging research, prior studies have applied structural covariance analysis to elucidate underlying coordinated morphological changes in brain aging and various brain diseases, but have had several limitations. They often relied on pre-defined neuroanatomical ROIs to construct inter- and intra-individual structural covariance networks. These a priori ROIs might not optimally reflect the molecular-functional characteristics of the brain. In addition, most population-based studies have investigated brain structural covariance within a relatively limited scope, such as within relatively small samples, over a relatively narrow age window (e.g., adolescence²), within a single disease (e.g., Parkinson's disease⁶), or within datasets lacking sufficient diversity in cohort characteristics or MRI scanner protocols. These have been imposed, in part, by limitations in both available cohort size and in the algorithmic implementation of structural covariance analysis, which has been computationally restricted to modest sample sizes when investigated at full image resolution. Lastly, prior studies have examined brain structural covariance at a single fixed ROI resolution/scale/granularity. While the optimal scale is unknown and may differ by the question of interest, the highly complex organization of the human brain may demonstrate structural covariance patterns that span multiple scales.^{7,8}

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

To address this gap, we modified our previously proposed orthogonally projective nonnegative matrix factorization (opNMF⁹) to its stochastic counterpart, sopNMF. This adaptation allowed us to train the model iteratively on large-scale neuroimaging datasets with a pre-defined number of PSCs (C). Non-negative matrix factorization has gained significant attention in neuroimaging due to its ability to reduce complex data into a sparse, part-based brain representation by projection onto a relatively small number of components (the PSCs). NMF has been shown to substantially improve interpretability and reproducibility compared to other unsupervised methods, such as PCA and ICA, thanks to the non-negative constraint that produces parcellation-like decompositions of complex signals. Our opNMF/sopNMF approach imposed an additional orthonormality constraint (Equation 1 in Method 1), further enhancing sparsity and facilitating clinical interpretability. In our previous work, we applied the opNMF method to 934 youths ages 8–20 to depict the coordinated growth of structural brain networks during adolescence – a period characterized by extensive remodeling of the human cortex to accommodate the rapid expansion of the behavioral repertoire². Remarkably, this study revealed PSCs that exhibited a cortical organization closely aligned with established functional brain networks, such as the well-known 7-network functional parcellation proposed by Yeo et al¹⁰. Notably, this alignment emerged without prior assumptions, was data-driven and hypothesisfree, and potentially reflected underlying neurobiological processes related to brain development and aging. Herein, we used large-scale neuroimaging data to investigate the underlying genetic determinant influencing such changes in structural covariance patterns in the human brain. We examined structural covariance of regional cortical and subcortical volume in the human brain using MRI from a diverse population of 50,699 people from 12 studies, 130 sites, and 12 countries, comprised of cognitively healthy individuals, as well as participants with

various diseases/conditions over their lifespan (ages 5 through 97). Herein we present results from coarse to fine scales corresponding to *C* = 32, 64, 128, 256, 512, and 1024. We hypothesized that PSCs at multiple scales could delineate the human brain's multi-factorial and multi-faceted morphological landscape and genetic architecture in healthy and diseased individuals. We examined the associations between these multi-scale PSCs and common genetic variants at different levels (*N*=8,469,833 SNPs). In total, 617 novel genomic loci were identified; key pathways (e.g., neurogenesis and reelin signaling) contributed to shaping structural covariance patterns in the human brain. In addition, we leveraged PSCs at multiple scales to better derive individualized imaging signatures of several diseases than any single-scale PSCs using support vector machines. All experimental results and the multi-scale PSCs were integrated into the MuSIC (Multi-scale Structural Imaging Covariance) atlas and made publicly accessible through the BRIDGEPORT (BRaIn knowleDGE PORTal) web portal: https://www.cbica.upenn.edu/bridgeport/. Table 1 provides an overview of the abbreviations used in the present study.

Table 1. Abbreviations used in the present study

188

189

Item	Abbreviation	Item	Abbreviation
Pattern of structural covariation	PSC	Independent component analysis	ICA
Genome-wide association study	GWAS	BRaIn knowleDGE PORTal	BRIDGEPORT
Orthogonal projective non-negative matrix factorization	opNMF	Multi-scale Structural Imaging Covariance	MuSIC
Stochastic orthogonal projective non-negative matrix factorization	sopNMF	Machine learning	ML
Principal component analysis	PCA	UK Biobank	UKBB
Imaging-based coordinate SysTem for AGing and NeurodeGenerative diseases	iSTAGING	Psychosis Heterogeneity Evaluated via Dimensional Neuroimaging	PHENOM
Single nucleotide polymorphism	SNP	Region of interest	ROI
Magnetic resonance imaging	MRI	Automated anatomical labeling	AAL
MUlti-atlas region Segmentation utilizing Ensembles	MUSE	Alzheimer's disease	AD
Spatial PAtterns for REcognition	SPARE	Support vector machine	SVM

Results

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209


210

211

212

We summarize this work in three units (I to III) outlined in Fig. 1. In Unit I (Fig. 1A), we present the stochastic orthogonally projective non-negative matrix factorization (sopNMF) algorithm (**Method 1**), optimized for large-scale multivariate structural covariance analysis. The sopNMF algorithm decomposes large-scale imaging data through online learning to overcome the memory limitations of opNMF. A subgroup of participants with multiple disease diagnoses and healthy controls (ages 5-97, training population, N=4000, **Method 2**) were sampled from the discovery set (N=32,440, Method 2); their MRI underwent a standard imaging processing pipeline (Method 3A). The processed images were then fit to sopNMF to derive the multi-scale PSCs (N=2003) from the loadings of the factorization (**Method 1**). We incorporate participants with various disease conditions because previous studies have demonstrated that inter-regional correlated patterns (i.e., depicting a network) show variations in healthy and diseased populations, albeit to a differing degree. 11 Multi-scale PSCs were extracted across the entire population and statistically harmonized¹² (**Method 3B**). Unit **II** (**Fig. 1B**) investigates the harmonized data for 2003 PSCs (13 PSCs have vanished in this process for C=1024; see Method 1) in two brain structural covariance analyses. Specifically, we performed i) GWAS (**Method 4**) that sought to discover associations of PSCs at single nucleotide polymorphism (SNP), gene, or gene set-level; and ii) pattern analysis via support vector machine (**Method 5**) to derive individualized imaging signatures of several brain diseases and conditions. Unit III (Fig. 1C) presents BRIDGEPORT, making these massive analytic resources publicly available to the imaging, genomics, and machine learning communities.





A) Unit I: the stochastic orthogonally projective non-negative matrix factorization (sopNMF) algorithm was applied to a large, disease-diverse population to derive multi-scale patterns of structural covariance (PSC) at different scales (*C*=32, 64, 128, 256, 512, and 1024; *C* represents the number of PSCs). **B)** Unit II: two types of analyses were performed in this study: Genomewide association studies (GWAS) relate each of the PSCs (*N*=2003) to common genetic variants; pattern analysis via machine learning demonstrates the utility of the multi-scale PSCs in deriving individualized imaging signatures of various brain pathologies. **C)** Unit III: BRIDGEPORT is a web portal that makes all resources publicly available for dissemination. As an illustration, a Manhattan plot for PSC (C64-3, the third PSC of the C64 atlas) and its 3D brain map are displayed.

Patterns of structural covariance via stochastic orthogonally projective non-negative

matrix factorization

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247


248

249

250

We first validated the sopNMF algorithm by showing that it converged to the global minimum of the factorization problem using the comparison population (N=800, Method 2). The sopNMF algorithm achieved similar reconstruction loss and sparsity as opNMF but at reduced memory demand (Supplementary eFigure 1). The lower memory requirements of sopNMF made it possible to generate multi-scale PSCs by jointly factorizing 4000 MRIs in the training population. The results of the algorithm were robust and obtained a high reproducibility index (RI) (Supplementary eMethod 2) in several reproducibility analyses: split-sample analysis (RI $= 0.76\pm0.27$), split-sex analysis (RI = 0.79 ± 0.27), and leave-one-site-out analysis (RI = 0.65-0.78 for C32 PSCs) (Supplementary eFigure 2). We then extracted the multi-scale PSCs in the discovery set (N=32,440) and the replication set (N=18,259, Method 2) for Unit II. These PSCs succinctly capture underlying neurobiological processes across the lifespan, including the effects of typical aging processes and various brain diseases. In addition, the multi-scale representation constructs a hierarchy of brain structure networks (e.g., PSCs in cerebellum regions), which models the human brain in a multi-scale topology. ^{7,13} Patterns of structural covariance are highly heritable The multi-scale PSCs are highly heritable (0.05 $< h^2 <$ 0.78), showing high SNP-based heritability estimates (h^2) (Method 4B) for the discovery set (Fig. 2). Specifically, the h^2 estimate was 0.49 ± 0.10 , 0.39 ± 0.14 , 0.29 ± 0.15 , 0.25 ± 0.15 , 0.27 ± 0.15 , 0.31 ± 0.15 for scales C=32, 64, 128, 256, 512 and 1024 of the PSCs, respectively. The Pearson correlation coefficient between the two independent estimates of h^2 was r = 0.94 (p-value < 10^{-6} , between the discovery and replication sets) in the UK Biobank (UKBB) data. The scatter plot of the two sets of h^2 estimates is shown in Supplementary eFigure 3. The h^2 estimates and p-values for all PSCs are detailed in **Supplementary eFile 1** (discovery set) and **eFile 2** (replication set). Our results confirm that brain structure is heritable to a large extent and identify the spatial distribution of the most highly heritable regions of the brain (e.g., subcortical gray matter structures and cerebellum regions).¹⁴

Figure 2: Patterns of structural covariance are highly heritable in the human brain.



Patterns of structural covariance (PSCs) of the human brain are highly heritable. The SNP-based heritability estimates are calculated for the multi-scale PSCs at different scales (*C*). PSCs surviving Bonferroni correction for multiple comparisons are depicted in color in the Manhattan plots (gray otherwise). Each PSC's heritability estimate (h2) was projected onto the 3D image space to show a statistical map of the brain at each scale *C*. The dotted line indicates each scale's top 10% of most heritable PSCs.

617 novel genomic loci of patterns of structural covariance

We discovered genomic locus-PSC pairwise associations (**Method 4C**, **Supplementary eMethod 5**) within the discovery set and then independently replicated these associations on the replication set. We found that 915 genomic loci had 3791 loci-PSC pairwise significant associations with 924 PSCs after Bonferroni correction (**Method 4G**) for the number of PSCs (p-value threshold per scale: 10.3 > -log₁₀[p-value] > 8.8) (**Supplementary eFile 3**, and **Fig. 3A**). Our results showed that the formation of these PSCs is largely polygenic; the associated SNPs might play a pleiotropic role in shaping these networks.

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292


293

294

Compared to previous literature, out of the 915 genomic loci, the multi-scale PSCs identified 617 novel genomic loci not previously associated with any traits or phenotypes in the GWAS Catalog¹⁵ (Supplementary eFile 4, Fig. 3B, query date: April 5th, 2023). These novel associations might indicate subtle neurobiological processes that are captured thanks to the biologically relevant structural covariance expressed by sopNMF. The multi-scale PSCs identified many novel associations by constraining this comparison to previous neuroimaging GWAS^{12,13} using T1w MRI-derived phenotypes (e.g., regions of interest from conventional brain atlases) (Fig 3B, Supplementary eTable 3, eFile 5, 6, and 7). Our UKBB replication set analysis (Method 4H) demonstrated that 3638 (96%) exact genomic locus-PSC associations were replicated at nominal significance ($-\log_{10}[p-value] > 1.31$), 2705 (72%) of which were significant after correction for multiple comparisons (**Method 4G**, - $\log_{10}[p\text{-value}] > 4.27$). We present this validation in **Supplementary eFile 8** from the replication set. The summary statistics, Manhattan, and QQ plots derived from the combined population (*N*=33,541) are presented in BRIDGEPORT. In addition to the abovementioned replication analyses, we also performed several sensitivity analyses (Supplementary eFigure 4a). We used the GWAS results (233 significant SNPs in 5 genomic loci) of the first PSC in C32 (C32_1) from the UKBB discovery set to demonstrate this. First, we replicated all the 233 significant SNPs in 5 genomic loci both at the nominal level ($-\log_{10}[p\text{-value}] > 1.31$), and the Bonferroni corrected p-value threshold ($-\log_{10}[p\text{-}$ value] > 3.67) using the combined discovery and replication sets (N=33,541) (Supplementary **eFigure 4b**), the 20,438 4ticipants with all ancestries in the discovery set (**Supplementary eFigure 4c**), and the 16,743 participants in the discovery set with four additional imaging-related covariates (3 parameters for the brain position in the lateral, longitudinal, and transverse

directions, and 1 parameter for the head motion from fMRI) (Supplementary eFigure 4d). While replicating the results in 2386 participants with non-European ancestries, we only replicated 41 SNPs (17.6%), passing the nominal significant threshold (Supplementary eFigure **4e**). Finally, only 14 SNPs (6.4%) were replicated when replicating the results using 1481 wholegenome sequencing (WGS) data from ADNI consolidated by the AI4AD consortium¹⁶ (Supplementary eFigure 4f). The low replication rates in other ancestries and independent disease-specific populations are expected due to population stratification, disease-specific effects, and reduced sample sizes. This further emphasizes the urge to enrich and diversify genetic research with non-European ancestries and disease-specific populations.

Figure 3: Patterns of structural covariance highlight novel genomic loci and pathways that shape the human brain.



A) Patterns of structural covariance (PSC) in the human brain are polygenic: the number of genomic loci of each PSC is projected onto the image space to show a statistical brain map characterized by the number (*C*) of PSCs. In addition, common genetic variants exert pleiotropic effects on the PSCs: circular plots showed the number of associated PSCs (histograms in blue color) of each genomic loci over the entire autosomal chromosome (1-22). The histogram was plotted for the number of PSCs for each genomic locus in the circular plots. **B)** Novel genomic loci revealed by the multi-scale PSCs compared to previous findings from the GWAS Catalog, ¹⁵ T1-weighted MRI GWAS^{4,5}, and the AAL atlas regions of interest. The green bar indicates the 617 novel genomic loci not previously associated with any clinical traits in GWAS Catalog; the black bar presents the loci identified in other studies that overlap (grey bar for loci in linkage disequilibrium) with the loci from our results; the yellow bar indicates the unique loci in other studies. **C)** Pathway enrichment analysis highlights six unique biological pathways and

328

329 330 331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

functional categories (after Bonferroni correction for 16,768 gene sets and the number of PSCs) that might influence the changes of PSCs. DSCAM: Down syndrome cell adhesion molecule. Gene set enrichment analysis highlights pathways that shape patterns of structural covariance For gene-level associations (**Method 4D**), we discovered that 164 genes had 2489 gene-PSC pairwise associations with 445 PSCs after Bonferroni correction for the number of genes and PSCs (p-value threshold: $8.6 > -\log_{10}[p-value] > 7.1$) (Supplementary eFile 9). Based on these gene-level p-values, we performed hypothesis-free gene set pathway analysis using MAGMA¹⁷(**Method 4E**): a more stringent correction for multiple comparisons was performed than the prioritized gene set enrichment analysis using GENE2FUN from FUMA (Method 4F and Fig. 4). We identified that six gene set pathways had 18 gene set-PSC pairwise associations with 17 PSCs after Bonferroni correction for the number of gene sets and PSCs $(N=16,768 \text{ and } C \text{ from } 32 \text{ to } 1024, \text{ p-value threshold: } 8.54 > -\log_{10}[\text{p-value}] > 7.03)$ (**Fig. 3C**, **Supplementary eFile 10).** These gene sets imply critical biological and molecular pathways that might shape brain morphological changes and development. The reelin signaling pathway regulates neuronal migration, dendritic growth, branching, spine formation, synaptogenesis, and synaptic plasticity. 18 The appendage morphogenesis and development pathways indicate how the anatomical structures of appendages are generated, organized, and progressed over time, often related to the cell adhesion pathway. These pathways elucidate how cells or tissues can be organized to create a complex structure like the human brain. ¹⁹ In addition, the integral component of the cytoplasmic side of the endoplasmic reticulum membrane is thought to form a continuous network of tubules and cisternae extending throughout neuronal dendrites and axons.²⁰ The DSCAM (Down syndrome cell adhesion molecule) pathway likely functions as a

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

cell surface receptor mediating axon pathfinding. Related proteins are involved in hemophilic intercellular interactions. 21 Lastly, Nikolsky et al. 22 defined genes from the breast cancer 20Q11 amplicon pathway that were involved in the brain might indicate the brain metastasis of breast cancer, which is usually a late event with deleterious effects on the prognosis.²³ In addition, previous findings^{24,25} revealed an inverse relationship between Alzheimer's disease and breast cancer, which might indicate a close genetic relationship between the disease and brain morphological changes mainly affecting the entorhinal cortex and hippocampus (PSC: C128_3 in **Fig. 4**). Illustrations of genetic loci and pathways forming two patterns of structural covariance To illustrate how underlying genetic underpinnings might form a specific PSC, we showcased two PSCs: C32_4 for the superior cerebellum and C128_3 for the hippocampus-entorhinal cortex. The two PSCs were highly heritable and polygenic in our GWAS using the entire UKBB data (Fig. 4, N=33,541). We used the FUMA²⁶ online platform to perform SNP2GENE for annotating the mapped genes and GENE2FUNC for prioritized gene set enrichment analyses (Method 4F). The superior cerebellum PSC was associated with genomic loci that can be mapped to 85 genes, which were enriched in many biological pathways, including psychiatric disorders, biological processes, molecular functions, and cellular components (e.g., apoptotic process, axon development, cellular morphogenesis, neurogenesis, and neuro differentiation). For example, apoptosis – the regulated cell destruction – is a complicated process that is highly involved in the development and maturation of the human brain and neurodegenerative diseases.²⁷ Neurogenesis – new neuron formation – is crucial when an embryo develops and

continues in specific brain regions throughout the lifespan.²⁸ All significant results of this prioritized gene set enrichment analysis are presented in **Supplementary eFile 11.**

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389


390

391

392

For the hippocampus-entorhinal cortex PSC, we mapped 45 genes enriched in gene sets defined from GWAS Catalog, including Alzheimer's disease and brain volume derived from hippocampal regions. The hippocampus and medial temporal lobe have been robust hallmarks of Alzheimer's disease.²⁹ In addition, these genes were enriched in the breast cancer 20Q11 amplicon pathway²² and the pathway of metastatic breast cancer tumors³⁰, which might indicate a specific distribution of brain metastases: the vulnerability of medial temporal lobe regions to breast cancer, ²³ or highlight an inverse association between Alzheimer's disease and breast cancer. 24 Lastly, the nuclear membrane encloses the cell's nucleus – the chromosomes reside inside – which is critical in cell formation activities related to gene expression and regulation. To further support the overlapping genetic underpinnings between this PSC and Alzheimer's disease, we calculated the genetic correlation ($r_g = -0.28$; p-value=0.01) using GWAS summary statistics from the hippocampus-entorhinal cortex PSC (i.e., 33,541 people of European ancestry) and a previous independent study of Alzheimer's disease³¹ (i.e., 63,926 people of European ancestry) using LDSC.³² All significant results of this prioritized gene set enrichment analysis are presented in Supplementary eFile 12.

Figure 4: Illustrations of multiple genetic loci and pathways shaping specific patterns of structural covariance



We demonstrate how underlying genomic loci and biological pathways might influence the formation, development, and changes of two specific PSCs: the 4th PSC of the C32 PSCs (C32_4) that resides in the superior part of the cerebellum and the 3rd PSC of the C128 PSCs (C128_3) that includes the bilateral hippocampus and entorhinal cortex. We first performed *SNP2GENE* to annotate the mapped genes in the Manhattan plots and then ran *GENE2FUNC* for

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425


426

the prioritized gene set enrichment analysis (Method 4F). The mapped genes are input genes for prioritized gene set enrichment analyses. The heat map shows the significant gene sets from the GWAS Catalog, curated genes, and gene ontology (GO) that survived the correction for multiple comparisons. We selectively present the schematics for three pathways: apoptosis, neurogenesis, and nuclear membrane function. Several other key pathways are highlighted in bold, and the 3D maps of the two PSCs are presented. Multi-scale patterns of structural covariance derive disease-related imaging signatures We used the multi-scale PSCs from a diverse population to derive imaging signatures that reflect brain development, aging, and the effects of several brain diseases. We investigate the added value of the multi-scale PSCs as building blocks of imaging signatures for several brain diseases and risk conditions using linear support vector machines (SVM) (Method 5).³³ The aim is to harness machine learning to drive a clinically interpretable metric for quantifying an individuallevel risk to each disease category. To this end, we define the signatures as SPARE-X (Spatial PAtterns for REcognition) indices, where X is the disease. For instance, SPARE-AD captures the degree of expression of an imaging signature of AD-related brain atrophy, which has been shown to offer diagnostic and prognostic value in prior studies.³⁴ The most discriminative indices in our samples were SPARE-AD and SPARE-MCI (Fig. **5**, **Supplementary eTable 4a** and **eFigure 5**). C=1024 achieved the best performance for the single-scale analysis (e.g., AD vs. controls; balanced accuracy: 0.90±0.02; Cohen's d: 2.50). Multi-scale representations derived imaging signatures that showed the largest effect sizes to classify the patients from the controls (**Fig. 5**) (e.g., AD vs. controls; balanced accuracy: 0.92±0.02; Cohen's d: 2.61). PSCs obtained better classification performance than both AAL (e.g., AD vs. controls; balanced accuracy: 0.82±0.02; Cohen's d: 1.81) and voxel-wise regional volumetric maps $(RAVENS)^{35}$ (e.g., AD vs. controls; balanced accuracy: 0.85 ± 0.02 ; Cohen's d: 2.04) (Supplementary eTable 4a and eFigure 5). Our classification results were higher than

previous baseline studies^{36,37}, which provided an open-source framework to objectively and reproducibly evaluate AD classification. Using the same cross-validation procedure and evaluation metric, they reported the highest balanced accuracy of 0.87 ± 0.02 to classify AD from healthy controls. Notably, our experiments followed good practices, employed rigorous cross-validation procedures, and avoided critical methodological flaws, such as data leakage or double-dipping (refer to critical reviews on this topic elsewhere^{36,38}).

To test the robustness of these SPARE indices, we performed leave-one-site-out analyses for SPARE-AD using the combined 2003 PSCs from all scales (**Supplementary eTable 4b**). Overall, holding the ADNI data out as independent test data resulted in a lower balanced accuracy (0.88 ± 0.02) compared to the other cases for AIBL (0.95 ± 0.02) and PENN data (0.95 ± 0.02) . The mean balanced accuracy (0.91 ± 0.02) aligns with the nested cross-validated results using the full sample (**Fig. 5**).

Figure 5: Individualized imaging signatures based on pattern analysis via machine learning.



443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

Imaging signatures (SPARE indices) of brain diseases, derived via supervised machine learning models, are more distinctive when formed from multi-scale PSCs than single-scale PSCs. The kernel density estimate plot depicts the distribution of the patient group (blue) in comparison to the healthy control group (red), reflecting the discriminative power of the diagnosis-specific SPARE (imaging signature) indices. We computed Cohen's d for each SPARE index between groups to present the effect size of its discrimination power. * represents the model with the largest Cohen's d for each SPARE index to separate the control vs. patient groups; # represents the model with the best performance with single-scale PSCs. Our results demonstrate that the multi-scale PSCs generally achieve the largest discriminative effect sizes (ES) (Supplementary **eTable 4a**). As a reference, Cohen's d of ≥ 0.2 , ≥ 0.5 , and ≥ 0.8 , respectively, refer to small, moderate, and large effect sizes. BRIDGEPORT: bridging knowledge across patterns of structural covariance, genomics, and clinical phenotypes We integrated our experimental results and the MuSIC atlas into the BRIDGEPORT online web portal. This online tool allows researchers to interactively browse the MuSIC atlas in 3D, query our experimental results via variants or PSCs, and download the GWAS summary statistics for further analyses. In addition, we allow users to search via conventional brain anatomical terms (e.g., the right thalamus proper) by automatically annotating traditional anatomic atlas ROIs, specifically from the MUSE atlas³⁹ (Supplementary eTable 5), to MuSIC PSCs based on their degree of overlaps (Supplementary eFigure 6). Open-source software dedicated to image processing, ³⁹ genetic quality check protocols, MuSIC generation with sopNMF, and machine learning³⁶ is also publicly available (see Code Availability for details).

Discussion

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

The current study investigates patterns of structural covariance in the human brain at multiple scales from a large population of 50,699 people and, importantly, a very diverse cohort allowing us to capture patterns of structural covariance emanating from normal and abnormal brain development and aging, as well as from several brain diseases. Through extensive examination of the genetic architecture of these multi-scale PSCs, we confirmed genetic hits from previous T1-weighted MRI GWAS and, more importantly, identified 617 novel genomic loci and molecular and biological pathways that collectively influence brain morphological changes and development over the lifespan. Using a hypothesis-free, data-driven approach to first derive these PSCs using brain MRIs, we then uncovered their genetic underpinnings and further showed their potential as building blocks to predict various diseases. All experimental results and code are encapsulated and publicly available in BRIDGEPORT for dissemination: https://www.cbica.upenn.edu/bridgeport/, to enable various neuroscience studies to investigate these structural covariance patterns in diverse contexts. Together, the current study highlighted the adoption of machine learning methods in brain imaging genomics and deepened our understanding of the genetic architecture of the human brain. Our findings reveal new insights into genetic underpinnings that influence structural covariance patterns in the human brain. Brain morphological development and changes are largely polygenic and heritable, and previous neuroimaging GWAS has not fully uncovered this genetic landscape. In contrast, genetic variants, as well as environmental, aging, and disease effects, exert pleiotropic effects in shaping morphological changes in different brain regions through specific biological pathways. The mechanisms underlying brain structural covariance are not yet fully understood. They may involve an interplay between common underlying genetic

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

factors, shared susceptibility to aging, and various brain pathologies, which affect brain growth or degeneration in coordinated brain morphological changes. Our data-driven, multi-scale PSCs identify the hierarchical structure of the brain under the principle of structural covariance and are associated with genetic factors at different levels, including SNPs, genes, and gene set pathways. These 617 novel genomic loci, as well as those previously identified, collectively shape brain morphological changes through many key biological and molecular pathways. These pathways are widely involved in reelin signaling, apoptotic processes, axonal development, cellular morphogenesis, neurogenesis, and neuro differentiation, ^{27,28} which may collectively influence the formation of structural covariance patterns in the brain. Strikingly, pathways involved in breast cancer shared overlapping genetic underpinnings evidenced in our MAGMA-based and prioritized (GENE2FUNC) gene set enrichment analyses (Fig. 3C and Fig. 4), which included specific pathways involved in breast cancer and metastatic breast cancer tumors. One previous study showed that common genes might mediate breast cancer metastasis to the brain, ²³ and a later study further corroborated that the metastatic spread of breast cancer to other organs (including the brain) accelerated during sleep in both mouse and human models.⁴⁰ We further showcased that this brain metastasis of breast cancer might be associated with specific neuropathologic processes, which were captured by PSCs data driven by Alzheimer's diseaserelated neuropathology. For example, the hippocampus-entorhinal cortex PSC (C128_3, Fig. 4) connected the bilateral hippocampus and medial temporal lobe – the salient hallmark of Alzheimer's disease. Our gene set enrichment analysis results further support this claim: the genes were enriched in the gene sets of Alzheimer's disease and breast cancer (Fig. 4). Previous research^{24,25} also found an inverse association between Alzheimer's disease and breast cancer. In addition, PSCs from the cerebellum were the most genetically influenced brain regions,

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

consistent with previous neuroimaging GWAS.^{4,5} The cerebral cortex has been thought to largely contribute to the unique mental abilities of humans. However, the cerebellum may also be associated with a much more comprehensive range of complex cognitive functions and brain diseases than initially thought.⁴¹ Our results confirmed that many genetic substrates might support different molecular pathways, resulting in cerebellar functional organization, high-order functions, and dysfunctions in various brain disorders. The current work demonstrates that appropriate machine learning analytics can be used to shed new light on brain imaging genetics. Previous neuroimaging GWAS leveraged multimodal imaging-derived phenotypes from conventional brain atlases^{4,5} (e.g., the AAL atlas). In contrast, multi-scale PSCs are purely data-driven and likely to reflect the dynamics of underlying normal and pathological neurobiological processes giving rise to structural covariance. The diverse training sample from which the PSCs were derived, including healthy and diseased individuals of a wide age range, enriched the diversity of such neurobiological processes influencing the PSCs. In addition, modeling structural covariance at multiple scales (i.e., multi-scale PSCs) indicated that disease effects could be robustly and complementarily identified across scales (Fig. 5), concordant with the paradigm of multi-scale brain modeling. ¹³ Imaging signatures of brain diseases, derived via supervised machine learning models, were consistently more distinctive when formed from multi-scale PSCs than single-scale PSCs. Multivariate learning techniques have gained significant prominence in neuroimaging and have recently attracted considerable attention in the domain of imaging genomics. These methods have proven valuable for analyzing complex and high-dimensional data, facilitating the exploration of relationships between imaging

features and genetic factors. For instance, the MOSTest, a multivariate GWAS approach,

preserves correlation structure among phenotypes via permutation on each SNP and derives a

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

genotype vector for testing the association across all phenotypes⁴². A separate study by Soheili-Nezhad et al. demonstrated that genetic components obtained through PCA or ICA applied to neuroimaging GWAS summary statistics exhibited greater reproducibility than raw univariate GWAS effect sizes⁴³. A recent study utilized a CNN-based autoencoder to discover new phenotypes and identify numerous novel genetic signals⁴⁴. Despite the effectiveness of these multivariate approaches in GWAS, they typically conduct phenotype engineering before performing GWAS without explicitly incorporating imaging genetic associations during the modeling process. Yang et al. recently conducted a study that employed generative adversarial networks (termed GeneSGAN⁴⁵) to integrate imaging and genetic variations within the modeling framework to address this limitation. By incorporating both modalities, their approach aimed to capture the complexity and heterogeneity of disease manifestations. MuSIC – with the strengths of being data-driven, multi-scale, and disease-effect informative – contributes to the century-old quest for a "universal" atlas in brain cartography⁴⁶ and is highly complementary to previously proposed brain atlases. For instance, Chen and colleagues⁴⁷ used a semi-automated fuzzy clustering technique with MRI data from 406 twins and parcellated the cortical surface area into a genetic covariance-informative brain atlas; MuSIC was data-driven by structural covariance. Glasser and colleagues⁴⁸ adopted a semi-automated parcellation procedure to create a multimodal cortex atlas from 210 healthy individuals. Although this method successfully integrates multimodal information from cortical folding, myelination, and functional connectivity, this semi-automatic approach requires significant resources, some with limited resolution. MuSIC allows flexible, multiple scales for delineating macroscopic brain topology; including patient samples exposes the model to sources of variability that may not be visible in healthy controls. Another pioneering endeavor is the Allen

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

populations.

Brain Atlas project, ⁴⁹ whose overarching goals of mapping the human brain to gene expression data via existing conventional atlases, identifying local gene expression patterns across the brain in a few individuals, and deepening our understanding of the human brain's differential genetic architecture, are complementary to ours – characterizing the global genetic architecture of the human brain, emphasizing pathogenic variability and morphological heterogeneity. Bridging knowledge across the brain imaging, genomics, and machine learning communities is another pivotal contribution of this work. BRIDGEPORT provides a platform to lower the entry barrier for whole-brain genetic-structural analyses, foster interdisciplinary communication, and advocate for research reproducibility. ^{36,50–53} The current study demonstrates the broad applicability of this large-scale, multi-omics platform across a spectrum of neurodegenerative and neuropsychiatric diseases. The present study has certain limitations. Firstly, the sopNMF method utilized in brain parcellation considers only imaging structural covariance and overlooks the genetic determinants contributing to forming these structural networks, as indicated by our GWAS findings. Consequently, further investigations are needed to integrate imaging and genetics into brain parcellation. Additionally, it is important to note that our GWAS analyses primarily involved participants of European ancestry. To enhance genetic findings for underrepresented ethnic groups, future studies should prioritize the inclusion of diverse ancestral backgrounds, thereby promoting a more comprehensive understanding of the genetic underpinnings across different

Methods

577

578

589

590

591

592

593

595

596

- Method 1: Structural covariance patterns via stochastic orthogonally projective non-
- 579 **negative matrix factorization**
- The sopNMF algorithm is a stochastic approximation built and extended based on opNMF^{9,54}.
- We consider a dataset of n MR images and d voxels per image. We represent the data as a
- matrix X where each column corresponds to a flattened image: $X = [x_1, x_2, ..., x_n], X \in \mathbb{R}^{d \times n}$.
- The sopNMF algorithm factorizes X into two low-rank (r) matrices $W \in \mathbb{R}^{d \times r}_{>0}$ and $H \in \mathbb{R}^{r \times n}_{>0}$
- under the constraints of non-negativity and column-orthonormality. Using the Frobenius norm,
- the loss of this factorization problem can be formulated as

$$\|X - WH\|_F^2$$

subject to
$$\mathbf{H} = \mathbf{W}^T \mathbf{X}$$
, $\mathbf{W} \ge 0$ and $\mathbf{W}^T \mathbf{W} = \mathbf{I}$ (1)

where *I* stands for the identity matrix. The columns $w_i \in \mathbb{R}^d$, $||w_i||^2 = 1, \forall i \in \{1..r\}$ of the so-

called component matrix $\mathbf{W} = [w_1, w_2, ..., w_r]$ are part-based representations promoting sparsity

in data in this lower-dimensional subspace. From this perspective, the loading coefficient matrix

H represents the importance (weights) of each feature above for a given image. Instead of

optimizing the non-convex problem in a batch learning paradigm (i.e., reading all images into

memory) as opNMF, 9 sopNMF subsamples the number of images at each iteration, thereby

significantly reducing its memory demand by randomly drawing data batches $X_b \in \mathbb{R}^{d \times b}_{\geq 0}$ of $b \leq$

n images (b is the batch size; b=32 was used in the current analyses); this is done without

replacement so that all data goes through the model once $(\lceil n/b \rceil)$. In this case, the updating rule

597 can be rewritten as

$$W_{t+1} = W_t \frac{\left(X_b X_b^T W\right)_t}{\left(W W^T X_b X_b^T W\right)_t} \quad (2)$$

We calculate the loss on the entire dataset at the end of each epoch (i.e., the loss is incremental across all batches) with the following expression:

$$\sum_{i=1}^{\lfloor n/b \rfloor} \| X_{b_{-i}} - WW^T X_{bi} \|_F^2$$
 (3)

We evaluated the training loss and the sparsity of *W* at the end of each iteration. Moreover, early stopping was implemented to improve training efficiency and alleviate overfitting. We summarize the sopNMF algorithm in **Supplementary Algorithm 1**. An empirical comparison between sopNMF and opNMF is detailed in **Supplementary eMethod 1**.

We applied sopNMF to the training population (N=4000). The component matrix W was sparse after the algorithm converged with a pre-defined maximum number of epochs (100 by default) with an early stopping criterion. To build the MuSIC atlas, we clustered each voxel (row-wise) into one of the r features/PSCs as follows:

$$\mathbf{M}_{j} = \operatorname{argmax}_{k}(\mathbf{W}_{j,k}) (4)$$

where M is a d-dimensional vector and $j \in \{1...d\}$. The j-th element of M equals k if $W_{j,k}$ is the maximum value of the j-th row. Intuitively, M indicates which of the r PSCs each voxel belongs to. We finally projected the vector $M \in \mathbb{R}^d_{\geq 0}$ into the original image space to visualize each PSC of the MuSIC atlas (**Fig. 1**). Of note, 13 PSCs have vanished in this process for C=1024: all 0 for these 13 vectors.

Method 2: Study population

We consolidated a large-scale multimodal consortium (*N*=50,699) consisting of imaging, cognition, and genetic data from 12 studies, 130 sites, and 12 countries (**Supplementary eTable**1): the Alzheimer's Disease Neuroimaging Initiative⁵⁵ (ADNI) (*N*=1765); the UK Biobank⁵⁶

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

(UKBB) (N=39,564); the Australian Imaging, Biomarker, and Lifestyle study of aging⁵⁷ (AIBL) (N=830); the Biomarkers of Cognitive Decline Among Normal Individuals in the Johns Hopkins University⁵⁸ (BIOCARD) (N=288); the Baltimore Longitudinal Study of Aging^{59,60} (BLSA) (N=1114); the Coronary Artery Risk Development in Young Adults⁶¹ (CARDIA) (N=892); the Open Access Series of Imaging Studies⁶² (OASIS) (N=983), PENN (N=807); the Women's Health Initiative Memory Study⁶³ (WHIMS) (N=995), the Wisconsin Registry for Alzheimer's Prevention⁶⁴ (WRAP) (N=116); the Psychosis Heterogeneity (evaluated) via dimEnsional NeurOiMaging⁶⁵ (PHENOM) (N=2125); and the Autism Brain Imaging Data Exchange⁶⁶ (ABIDE) (*N*=1220). We present the demographic information of the population under study in **Supplementary eTable 1.** This large-scale consortium reflects the diversity of MRI scans over different races, disease conditions, and ages over the lifespan. To be concise, we defined four populations or data sets per analysis across the paper: Discovery set: It consists of a multi-disease and lifespan population that includes participants from all 12 studies (N=32,440). Note that this population does not contain the entire UKBB population but only our first download (July 2017, N=21,305). Replication set: We held 18,259 participants from the UKBB dataset to replicate the GWAS results. We took these data from our second download of the UKBB dataset (November 2021, *N*=18,259). Training population: We randomly drew 250 patients (PT), including AD, MCI, SCZ, ASD, MDD, HTN (hypertension), DM (diabetes mellitus), and 250 healthy controls (CN) per decade from the discovery set, ensuring that the PT and CN groups have similar sex, study and age distributions. The resulting set of 4000 imaging data was used

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

to generate the MuSIC atlas with the sopNMF algorithm. The rationale is to maximize variability across a balanced sample of multiple diseases or risk conditions, age, and study protocols rather than overfit the entire data by including all images in training. Comparison population: To validate sopNMF compared to the original opNMF algorithm, we randomly subsampled 800 participants from the training population (100) per decade for balanced CN and PT). For this scale of sample size, opNMF can load all images into memory for batch learning.⁶⁷ All individual studies were approved by their local corresponding Institutional Review Boards (IRB). The iSTAGING and PHENOM consortia consolidated all individual imaging and clinical data; imputed genotype data were directly downloaded from the UKBB website. Data from the UKBB for this project pertains to application 35148. For iSTAGING, the IRB at the University of Pennsylvania (protocol number: 825722) reviewed the research proposal on August 31st, 2016, and updated it on August 31st, 2022. No human subjects were recruited or scanned. Existing de-identified data will be used in this mega-analysis study pooling data from 17 studies: BLSA, ADNI1, ADNI2, ADNI3, ACCORD-MIND, LookAhead, SPRINT, CARDIA, MESA, SHIP, BIOCARD, WRAP, Penn-ADC, WHIMS-MRI, AIBL, OASIS, UKBB, MESA, HANDLS. For PHENOM, the IRB at the University of Pennsylvania (protocol number: 828077) reviewed the research proposal on August 19th, 2017. No human subjects were recruited or scanned. Existing de-identified data will be used in this meta-analysis study pooling data from 10 studies at Penn, Ludwick-Maximmilian University of Munich, Kings College-London, University of Utrecht, University of Melbourne, University of Cantabria, University of Sao Paolo, Xijing Hospital Shaanxi, Tianjin Anning Hospital, and Institute of Mental Health Peking University.

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

Method 3: Image processing and statistical harmonization (A): Image processing. Images that passed the quality check (Supplementary eMethod 4) were first corrected for magnetic field intensity inhomogeneity. ⁶⁸ Voxel-wise regional volumetric maps (RAVENS)³⁵ for each tissue volume were then generated by using a registration method to spatially align the skull-stripped images to a template in MNI-space. ⁶⁹ We applied sopNMF to the RAVENS maps to derive MuSIC. (B): Statistical harmonization of MuSIC PSCs: We applied MuSIC to the entire population (N=50,699) to extract the multi-scale PSCs. Specifically, MuSIC was applied to each individual's RAVENS gray matter map to extract the sum of brain volume in each PSC. Subsequently, the PSCs were statistically harmonized by an extensively validated approach, i.e., ComBat-GAM ¹² (Supplementary eMethod 3) to account for site-related differences in the imaging data. After harmonization, the PSCs were normally distributed (skewness = 0.11 ± 0.17 , and kurtosis = 0.67±0.68) (Supplementary eFigure 7A and B). To alleviate the potential violation of normal distribution in downstream statistical learning, we quantile-transformed all PSCs. In agreement with the literature, ^{70,71} males were found to have larger brain volumes than females on average (Supplementary eFigure 7C). Overall, the Combat-GAM model slightly improved data normality across sites (Supplementary eFigure 7E-H). The AAL ROIs underwent the same statistical harmonization procedure. **Method 4: Genetic analyses**

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

Genetic analyses were restricted to the discovery and replication set from UKBB (**Method 2**). We processed the array genotyping and imputed genetic data (SNPs). The two data sets went through a "best-practice" imaging-genetics quality check (QC) protocol (Method 4A) and were restricted to participants of European ancestry. This resulted in 18,052 participants and 8,430,655 SNPs for the discovery set and 15,243 participants and 8,470,709 SNPs for the replication set. We reperformed the genetic QC and genetic analyses for the combined populations for BRIDGEPORT, resulting in 33,541 participants and 8,469,833 SNPs. Method 4G details the correction for multiple comparisons throughout our analyses. (A): Genetic data quality check protocol. First, we excluded related individuals (up to 2nddegree) from the complete UKBB sample (N=488,377) using the KING software for family relationship inference.⁷² We then removed duplicated variants from all 22 autosomal chromosomes. We also excluded individuals for whom either imaging or genetic data were not available. Individuals whose genetically identified sex did not match their self-acknowledged sex were removed. Other excluding criteria were: i) individuals with more than 3% of missing genotypes; ii) variants with minor allele frequency (MAF) of less than 1%; iii) variants with larger than 3% missing genotyping rate; iv) variants that failed the Hardy-Weinberg test at 1×10^{-10} . To adjust for population stratification, ⁷³ we derived the first 40 genetic principle components (PC) using the FlashPCA software⁷⁴. The genetic pipeline was also described elsewhere⁷⁵. (B): Heritability estimates and genome-wide association analysis. We estimated the SNPbased heritability explained by all autosomal genetic variants using GCTA-GREML.⁷⁶ We adjusted for confounders of age (at imaging), age-squared, sex, age-sex interaction, age-squared-

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

sex interaction, ICV, and the first 40 genetic principal components (PC), guided by a previous neuroimaging GWAS⁴. In addition, Elliot et al.⁵ investigated more than 200 confounders in another study. Therefore, our sensitivity analyses included four additional imaging-related covariates (i.e., brain positions and head motion). One-side likelihood ratio tests were performed to derive the heritability estimates. In GWAS, we performed a linear regression for each PSC and included the same covariates as in the heritability estimates using PLINK.⁷⁷ (C): Identification of novel genomic loci. Using PLINK, we clumped the GWAS summary statistics based on their linkage disequilibrium to identify the genomic loci (see **Supplementary eMethod 5** for the definition of the index, candidate, independent significant, lead SNP, and genomic locus). In particular, the threshold for significance was set to 5×10^{-8} (clump-p1) for the index SNPs and 0.05 (clump-p2) for the candidate SNPs. The threshold for linkage disequilibrium-based clumping was set to 0.60 (*clump-r2*) for **independent significant SNPs** and 0.10 for lead SNPs. The linkage disequilibrium physical-distance threshold was 250 kilobases (clump-kb). Genomic loci consider linkage disequilibrium (within 250 kilobases) when interpreting the association results. The GWASRAPIDD⁷⁸ package (version: 0.99.14) was then used to query the genomic loci for any previously-reported associations with clinical phenotypes documented in the NHGRI-EBI GWAS Catalog¹⁵ (p-value $< 1.0 \times 10^{-5}$, default inclusion value of GWAS Catalog). We defined a genomic locus as novel when it was not present in GWAS Catalog (query date: April 5th, 2023). (D): Gene-level associations with MAGMA. We performed gene-level association analysis using MAGMA.¹⁷ First, gene annotation was performed to map the SNPs (reference variant

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

location from Phase 3 of 1,000 Genomes for European ancestry) to genes (human genome Build 37) according to their physical positions. The second step was to perform the gene analysis based on the GWAS summary statistics to obtain gene-level p-values between the pairwise 2003 PSCs and the 18,097 protein-encoding genes containing valid SNPs. (E): Hypothesis-free gene set enrichment analysis with MAGMA. Using the gene-level association p-values, we performed gene set enrichment analysis using MAGMA. Gene sets were obtained from Molecular Signatures Database (MsigDB, v7.5.1),⁷⁹ including 6366 curated gene sets and 10,402 Gene Ontology (GO) terms. All other parameters were set by default for MAGMA. This hypothesis-free analysis resulted in a more stringent correction for multiple comparisons (i.e., by the total number of tested genes and PSCs) than the FUMA-prioritized gene set enrichment analysis (see below F). (F): FUMA analyses for the illustrations of specific PSCs. In SNP2GENE, three different methods were used to map the SNPs to genes. First, positional mapping maps SNPs to genes if the SNPs are physically located inside a gene (a 10 kb window by default). Second, expression quantitative trait loci (eQTL) mapping maps SNPs to genes showing a significant eQTL association. Lastly, chromatin interaction mapping maps SNPs to genes when there is a significant chromatin interaction between the disease-associated regions and nearby or distant genes.²⁶ In addition, GENE2FUNC studies the expression of prioritized genes and tests for the enrichment of the set of genes in pre-defined pathways. We used the mapped genes as prioritized genes. The background genes were specified as all genes in FUMA, and all other parameters were set by default. We only reported gene sets with adjusted p-value < 0.05.

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

(G): Correction for multiple comparisons. We practiced a conservative procedure to control for the multiple comparisons. In the case of GWAS, we chose the default genome-wide significant threshold (5.0x10⁻⁸, and 0.05 for all other analyses) and independently adjusted for multiple comparisons (Bonferroni methods) at each scale by the number of PSCs. We corrected the p-values for the number of phenotypes (N=6) for genetic correlation analyses. We adjusted the p-values for the number of PSCs at each scale for heritability estimates. For gene analyses, we controlled for both the number of PSCs at each scale and the number of genes. We adopted these strategies per analysis to correct the multiple comparisons because PSCs of different scales are likely hierarchical and correlated – avoiding the potential of "overcorrection". (H): Replication analysis for genome-wide association studies. We performed GWAS by fitting the same linear regressing models as the discovery set. Also, following the same procedure for consistency, we corrected the multiple comparisons using the Bonferroni method. We corrected it for the number of genomic loci (N=915) found in the discovery set with a nominal p-value of 0.05, which thereby resulted in a stringent test with an equivalent p-value threshold of 3.1×10^{-5} (i.e., $(-\log_{10}[p\text{-value}] = 4.27)$). We performed a replication for the 915 genomic loci, but, in reality, SNPs in linkage disequilibrium with the genomic loci are likely highly significant. Method 5: Pattern analysis via machine learning for individualized imaging signatures SPARE-AD captures the degree of expression of an imaging signature of AD, and prior studies have shown its diagnostic and prognostic values.³⁴ Here, we extended the concept of the SPARE

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

imaging signature to multiple diseases (SPARE-X, X represents disease diagnoses). Following our reproducible open-source framework³⁷, we performed nested cross-validation (Supplementary eMethod 6) for the machine learning models and derived imaging signatures to quantify individualized disease vulnerability. **SPARE indices.** MuSIC PSCs were fit into a linear support vector machine (SVM) to derive SPARE-AD, MCI, SCZ, DM, HTN, MDD, and ASD. Specifically, the SVM aims to classify the patient group (e.g., AD) from the control group and outputs a continuous variable (i.e., the SPARE indices), which indicates the proximity of each participant to the hyperplane in either the patient or control space. We compared the classification performance using different sets of features: i) the single-scale PSC from 32 to 1024, ii) the multi-scale PSCs by combining all features (with and without feature selections embedded in the CV); iii) the ROIs from the AAL atlas; and iv) voxel-wise RAVENS maps. The samples selected for each task are presented in Supplementary eTable 2. No statistical methods were used to predetermine the sample size. The experiments were not randomized, and the investigators were not blinded to allocation during experiments and outcome assessment.

Data Availability

The GWAS summary statistics corresponding to this study are publicly available on the

BRIDGEPORT web portal (https://www.cbica.upenn.edu/bridgeport/) and the MEDICINE web

portal (https://labs.loni.usc.edu/medicine/). The GWAS summary statistics used in the genetic

correlation analyses were fetched from the GWAS Catalog platform

(https://www.ebi.ac.uk/gwas), although each study provided the original links; The GWAS

Catalog platform was used to query if the SNPs identified by MuSIC were previously reported.

Code Availability

The software and resources used in this study are all publicly available:

• sopNMF: https://pypi.org/project/sopnmf/, MuSIC, and sopNMF (developed for this study)

• BRIDGEPORT: https://www.cbica.upenn.edu/bridgeport/, (developed for this study)

• MLNI: https://pypi.org/project/mlni/, machine learning (developed for this study)

• MUSE: https://www.med.upenn.edu/sbia/muse.html, image preprocessing

• PLINK: https://www.cog-genomics.org/plink/, GWAS

• GCTA: https://www.cog-genomics.org/plink/, GWAS

• LDSC: https://github.com/bulik/ldsc, genetic correlation estimates

• LDSC: https://github.com/bulik/ldsc, genetic correlation estimates

• MAGMA: https://ctg.cncr.nl/software/magma, gene analysis

• GWASRAPIDD: https://rmagno.eu/gwasrapidd/articles/gwasrapidd.html, GWAS

Catalog query

• MsigDB: https://www.gsea-msigdb.org/gsea/msigdb/, gene sets database

Competing Interests

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

DAW served as Site PI for studies by Biogen, Merck, and Eli Lilly/Avid. He has received consulting fees from GE Healthcare and Neuronix. He is on the DSMB for a trial sponsored by Functional Neuromodulation. AJS receives support from multiple NIH grants (P30 AG010133, P30 AG072976, R01 AG019771, R01 AG057739, U01 AG024904, R01 LM013463, R01 AG068193, T32 AG071444, and U01 AG068057 and U01 AG072177). He has also received support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (in-kind contribution of PET tracer precursor); Bayer Oncology (Scientific Advisory Board); Eisai (Scientific Advisory Board); Siemens Medical Solutions USA, Inc. (Dementia Advisory Board); Springer-Nature Publishing (Editorial Office Support as Editor-in-Chief, Brain Imaging, and Behavior). OC reports having received consulting fees from AskBio (2020) and Therapanacea (2022), having received payments for writing a lay audience short paper from Expression Santé (2019), and that his laboratory has received grants (paid to the institution) from Qynapse (2017-present). Members of his laboratory have co-supervised a Ph.D. thesis with myBrainTechnologies (2016-2019) and with Qynapse (2017-present). OC's spouse is an employee and holds stock options of myBrainTechnologies (2015-present). OC has a patent registered at the International Bureau of the World Intellectual Property Organization (PCT/IB2016/0526993, Schiratti J-B, Allassonniere S, Colliot O, Durrleman S, A method for determining the temporal progression of a biological phenomenon and associated methods and devices) (2017). ME receives support from multiple NIH grants, the Alzheimer's Association, and the Alzheimer's Therapeutic Research Institute. MZ serves as a consultant and/or speaker for the following pharmaceutical companies: Eurofarma, Lundbeck, Abbott, Greencare, Myralis, and Elleven Healthcare.

Authors' contributions

Dr. Wen takes full responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Wen, Davatzikos

Acquisition, analysis, or interpretation of data: Wen, Nasrallah, Davatzikos, Abdulkadi,

Satterthwaite, Dazzan, Kahn, Schnack, Zanetti, Meisenzahl, Busatto, Crespo-Facorro, Pantelis,

Wood, Zhuo, Koutsouleris, Wittfeld, Grabe, Marcus, LaMontagne, Heckbert, Austin, Launer,

Espeland, Masters, Maruff, Fripp, Johnson, Morris, Albert, Resnick, Saykin, Thompson, Li,

Wolf, Raquel Gur, Ruben Gur, Shinohara, Tosun-Turgut, Fan, Shou, Erus, Wolk

Drafting of the manuscript: Wen, Nasrallah, Davatzikos

Critical revision of the manuscript for important intellectual content: all authors

Statistical and genetic analysis: Wen

References

- 1. Alexander-Bloch, A., Giedd, J. N. & Bullmore, E. Imaging structural co-variance between
- 855 human brain regions. *Nat Rev Neurosci* **14**, 322–336 (2013).
- 856 2. Sotiras, A. et al. Patterns of coordinated cortical remodeling during adolescence and their
- associations with functional specialization and evolutionary expansion. *Proc Natl Acad Sci*
- 858 *USA* **114**, 3527–3532 (2017).
- 859 3. Blank, S. C., Scott, S. K., Murphy, K., Warburton, E. & Wise, R. J. S. Speech production:
- Wernicke, Broca and beyond. *Brain* **125**, 1829–1838 (2002).
- 4. Zhao, B. et al. Genome-wide association analysis of 19,629 individuals identifies variants
- influencing regional brain volumes and refines their genetic co-architecture with cognitive
- and mental health traits. *Nat Genet* **51**, 1637–1644 (2019).
- 5. Elliott, L. T. et al. Genome-wide association studies of brain imaging phenotypes in UK
- 865 Biobank. *Nature* **562**, 210–216 (2018).
- 866 6. Vignando, M. et al. Mapping brain structural differences and neuroreceptor correlates in
- Parkinson's disease visual hallucinations. *Nat Commun* **13**, 519 (2022).
- 868 7. Bassett, D. S. & Siebenhühner, F. Multiscale Network Organization in the Human Brain. in
- Multiscale Analysis and Nonlinear Dynamics 179–204 (John Wiley & Sons, Ltd, 2013).
- 870 doi:10.1002/9783527671632.ch07.
- 871 8. Schaefer, A. et al. Local-Global Parcellation of the Human Cerebral Cortex from Intrinsic
- Functional Connectivity MRI. Cerebral Cortex 28, 3095–3114 (2018).
- 9. Sotiras, A., Resnick, S. M. & Davatzikos, C. Finding imaging patterns of structural
- covariance via Non-Negative Matrix Factorization. *NeuroImage* **108**, 1–16 (2015).

- 10. Thomas Yeo, B. T. et al. The organization of the human cerebral cortex estimated by
- intrinsic functional connectivity. *Journal of Neurophysiology* **106**, 1125–1165 (2011).
- 11. Seeley, W. W., Crawford, R. K., Zhou, J., Miller, B. L. & Greicius, M. D.
- Neurodegenerative diseases target large-scale human brain networks. *Neuron* **62**, 42–52
- 879 (2009).
- 880 12. Pomponio, R. et al. Harmonization of large MRI datasets for the analysis of brain imaging
- patterns throughout the lifespan. *Neuroimage* **208**, 116450 (2020).
- 882 13. Betzel, R. F. & Bassett, D. S. Multi-scale brain networks. *NeuroImage* **160**, 73–83 (2017).
- 883 14. Roshchupkin, G. V. et al. Heritability of the shape of subcortical brain structures in the
- general population. *Nat Commun* **7**, 13738 (2016).
- 885 15. Buniello, A. et al. The NHGRI-EBI GWAS Catalog of published genome-wide association
- studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res* **47**, D1005–D1012
- 887 (2019).
- 888 16. Wen, J. et al. Genetic, clinical underpinnings of subtle early brain change along
- Alzheimer's dimensions. 2022.09.16.508329 Preprint at
- 890 https://doi.org/10.1101/2022.09.16.508329 (2022).
- 17. Leeuw, C. A. de, Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-
- Set Analysis of GWAS Data. *PLOS Computational Biology* **11**, e1004219 (2015).
- 893 18. Jossin, Y. Reelin Functions, Mechanisms of Action and Signaling Pathways During Brain
- Development and Maturation. *Biomolecules* **10**, E964 (2020).
- 895 19. Gilbert, S. F. Morphogenesis and Cell Adhesion. *Developmental Biology. 6th edition*
- 896 (2000).

- 897 20. Wu, Y. et al. Contacts between the endoplasmic reticulum and other membranes in
- 898 neurons. *Proc Natl Acad Sci U S A* **114**, E4859–E4867 (2017).
- 899 21. Ly, A. et al. DSCAM Is a Netrin Receptor that Collaborates with DCC in Mediating
- 900 Turning Responses to Netrin-1. *Cell* **133**, 1241–1254 (2008).
- 901 22. Nikolsky, Y. et al. Genome-wide functional synergy between amplified and mutated genes
- 902 in human breast cancer. *Cancer Res* **68**, 9532–9540 (2008).
- 903 23. Bos, P. D. et al. Genes that mediate breast cancer metastasis to the brain. *Nature* **459**,
- 904 1005–1009 (2009).
- 905 24. Lanni, C., Masi, M., Racchi, M. & Govoni, S. Cancer and Alzheimer's disease inverse
- relationship: an age-associated diverging derailment of shared pathways. *Mol Psychiatry*
- 907 **26**, 280–295 (2021).
- 908 25. Shafi, O. Inverse relationship between Alzheimer's disease and cancer, and other factors
- contributing to Alzheimer's disease: a systematic review. *BMC Neurol* **16**, 236 (2016).
- 910 26. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
- annotation of genetic associations with FUMA. *Nat Commun* **8**, 1826 (2017).
- 912 27. Yuan, J. & Yankner, B. A. Apoptosis in the nervous system. *Nature* **407**, 802–809 (2000).
- 913 28. Steiner, E., Tata, M. & Frisén, J. A fresh look at adult neurogenesis. *Nat Med* 25, 542–543
- 914 (2019).
- 915 29. de Flores, R. et al. Medial Temporal Lobe Networks in Alzheimer's Disease: Structural and
- 916 Molecular Vulnerabilities. *J Neurosci* **42**, 2131–2141 (2022).
- 917 30. Ginestier, C. et al. Prognosis and gene expression profiling of 20q13-amplified breast
- 918 cancers. Clin Cancer Res 12, 4533–4544 (2006).

- 919 31. Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new
- 920 risk loci and implicates Aβ, tau, immunity and lipid processing. *Nat Genet* **51**, 414–430
- 921 (2019).
- 922 32. Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from
- polygenicity in genome-wide association studies. *Nat Genet* **47**, 291–295 (2015).
- 924 33. Davatzikos, C. Machine learning in neuroimaging: Progress and challenges. *NeuroImage*
- 925 **197**, 652–656 (2019).
- 926 34. Davatzikos, C., Xu, F., An, Y., Fan, Y. & Resnick, S. M. Longitudinal progression of
- Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index. *Brain*
- 928 **132**, 2026–2035 (2009).
- 929 35. Davatzikos, C., Genc, A., Xu, D. & Resnick, S. M. Voxel-based morphometry using the
- 930 RAVENS maps: methods and validation using simulated longitudinal atrophy. *Neuroimage*
- 931 **14**, 1361–1369 (2001).
- 932 36. Wen, J. et al. Convolutional neural networks for classification of Alzheimer's disease:
- Overview and reproducible evaluation. *Medical Image Analysis* **63**, 101694 (2020).
- 934 37. Samper-González, J. et al. Reproducible evaluation of classification methods in
- Alzheimer's disease: Framework and application to MRI and PET data. *NeuroImage* **183**,
- 936 504–521 (2018).
- 937 38. Kriegeskorte, N., Simmons, W. K., Bellgowan, P. S. F. & Baker, C. I. Circular analysis in
- 938 systems neuroscience: the dangers of double dipping. *Nat. Neurosci.* **12**, 535–540 (2009).
- 939 39. Doshi, J. et al. MUSE: MUlti-atlas region Segmentation utilizing Ensembles of registration
- algorithms and parameters, and locally optimal atlas selection. *Neuroimage* **127**, 186–195
- 941 (2016).

- 942 40. Diamantopoulou, Z. et al. The metastatic spread of breast cancer accelerates during sleep.
- 943 *Nature* **607**, 156–162 (2022).
- 944 41. Barton, R. A. & Venditti, C. Rapid Evolution of the Cerebellum in Humans and Other
- 945 Great Apes. Curr Biol 27, 1249–1250 (2017).
- 946 42. van der Meer, D. et al. Understanding the genetic determinants of the brain with MOSTest.
- 947 *Nat Commun* **11**, 3512 (2020).
- 948 43. Soheili-Nezhad, S., Beckmann, C. F. & Sprooten, E. Reproducibility of Principal and
- Independent Genomic Components of Brain Structure and Function. 2022.07.13.499912
- 950 Preprint at https://doi.org/10.1101/2022.07.13.499912 (2022).
- 951 44. Patel, K. et al. New phenotype discovery method by unsupervised deep representation
- learning empowers genetic association studies of brain imaging. 2022.12.10.22283302
- 953 Preprint at https://doi.org/10.1101/2022.12.10.22283302 (2022).
- 954 45. Yang, Z. et al. Gene-SGAN: a method for discovering disease subtypes with imaging and
- genetic signatures via multi-view weakly-supervised deep clustering. ArXiv
- 956 arXiv:2301.10772v1 (2023).
- 957 46. Eickhoff, S. B., Yeo, B. T. T. & Genon, S. Imaging-based parcellations of the human brain.
- 958 *Nat Rev Neurosci* **19**, 672–686 (2018).
- 959 47. Chen, C.-H. *et al.* Hierarchical Genetic Organization of Human Cortical Surface Area.
- 960 *Science* **335**, 1634–1636 (2012).
- 961 48. Glasser, M. F. et al. A multi-modal parcellation of human cerebral cortex. *Nature* **536**, 171–
- 962 178 (2016).
- 963 49. Sunkin, S. M. et al. Allen Brain Atlas: an integrated spatio-temporal portal for exploring the
- central nervous system. *Nucleic Acids Res* **41**, D996–D1008 (2013).

- 965 50. Munafò, M. R. et al. A manifesto for reproducible science. Nat Hum Behav 1, 1–9 (2017).
- 966 51. Poldrack, R. A. et al. Scanning the horizon: towards transparent and reproducible
- 967 neuroimaging research. *Nat. Rev. Neurosci.* **18**, 115–126 (2017).
- 968 52. Routier, A. et al. Clinica: An Open-Source Software Platform for Reproducible Clinical
- Neuroscience Studies. *Frontiers in Neuroinformatics* **15**, 39 (2021).
- 970 53. Wen, J. et al. Reproducible Evaluation of Diffusion MRI Features for Automatic
- 971 Classification of Patients with Alzheimer's Disease. *Neuroinformatics* **19**, 57–78 (2021).
- 972 54. Zhirong Yang & Oja, E. Linear and Nonlinear Projective Nonnegative Matrix
- 973 Factorization. *IEEE Trans. Neural Netw.* **21**, 734–749 (2010).
- 974 55. Petersen, R. C. et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical
- 975 characterization. *Neurology* **74**, 201–209 (2010).
- 976 56. Miller, K. L. et al. Multimodal population brain imaging in the UK Biobank prospective
- 977 epidemiological study. *Nat Neurosci* **19**, 1523–1536 (2016).
- 978 57. Ellis, K. A. *et al.* The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging:
- methodology and baseline characteristics of 1112 individuals recruited for a longitudinal
- study of Alzheimer's disease. *Int. Psychogeriatr.* **21**, 672–687 (2009).
- 981 58. Soldan, A. et al. Relationship of medial temporal lobe atrophy, APOE genotype, and
- cognitive reserve in preclinical Alzheimer's disease. *Hum Brain Mapp* **36**, 2826–2841
- 983 (2015).
- 984 59. Resnick, S. M., Pham, D. L., Kraut, M. A., Zonderman, A. B. & Davatzikos, C.
- Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. J
- 986 *Neurosci* **23**, 3295–3301 (2003).

- 987 60. Resnick, S. M. et al. One-year age changes in MRI brain volumes in older adults. Cereb
- 988 *Cortex* **10**, 464–472 (2000).
- 989 61. Friedman, G. D. et al. CARDIA: study design, recruitment, and some characteristics of the
- 990 examined subjects. *J Clin Epidemiol* **41**, 1105–1116 (1988).
- 991 62. LaMontagne, P. J. et al. OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive
- Dataset for Normal Aging and Alzheimer Disease. 2019.12.13.19014902 Preprint at
- 993 https://doi.org/10.1101/2019.12.13.19014902 (2019).
- 994 63. Resnick, S. M. et al. Postmenopausal hormone therapy and regional brain volumes: the
- 995 WHIMS-MRI Study. *Neurology* **72**, 135–142 (2009).
- 996 64. Johnson, S. C. et al. The Wisconsin Registry for Alzheimer's Prevention: A review of
- 997 findings and current directions. Alzheimer's & Dementia: Diagnosis, Assessment & Disease
- 998 *Monitoring* **10**, 130–142 (2018).
- 999 65. Chand, G. B. et al. Two distinct neuroanatomical subtypes of schizophrenia revealed using
- machine learning. *Brain* **143**, 1027–1038 (2020).
- 1001 66. Di Martino, A. et al. Enhancing studies of the connectome in autism using the autism brain
- imaging data exchange II. *Sci Data* **4**, 170010 (2017).
- 1003 67. Shalev-Shwartz, S., Singer, Y. & Ng, A. Y. Online and batch learning of pseudo-metrics. in
- 1004 Proceedings of the twenty-first international conference on Machine learning 94
- 1005 (Association for Computing Machinery, 2004). doi:10.1145/1015330.1015376.
- 1006 68. Tustison, N. J. et al. N4ITK: improved N3 bias correction. IEEE Trans. Med. Imaging 29,
- 1007 1310–1320 (2010).
- 1008 69. Ou, Y., Sotiras, A., Paragios, N. & Davatzikos, C. DRAMMS: Deformable Registration via
- Attribute Matching and Mutual-Saliency Weighting. *Med Image Anal* **15**, 622–639 (2011).

- 1010 70. Coupé, P., Catheline, G., Lanuza, E., Manjón, J. V. & Initiative, for the A. D. N. Towards a
- unified analysis of brain maturation and aging across the entire lifespan: A MRI analysis.
- 1012 Human Brain Mapping **38**, 5501–5518 (2017).
- 1013 71. Bethlehem, R. a. I. et al. Brain charts for the human lifespan. 2021.06.08.447489
- 1014 https://www.biorxiv.org/content/10.1101/2021.06.08.447489v1 (2021)
- 1015 doi:10.1101/2021.06.08.447489.
- 1016 72. Manichaikul, A. et al. Robust relationship inference in genome-wide association studies.
- 1017 *Bioinformatics* **26**, 2867–2873 (2010).
- 1018 73. Price, A. L., Zaitlen, N. A., Reich, D. & Patterson, N. New approaches to population
- stratification in genome-wide association studies. *Nat Rev Genet* **11**, 459–463 (2010).
- 1020 74. Abraham, G., Qiu, Y. & Inouye, M. FlashPCA2: principal component analysis of Biobank-
- scale genotype datasets. *Bioinformatics* **33**, 2776–2778 (2017).
- 1022 75. Wen, J. et al. Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical
- Symptoms, and Genetics Among Patients With Late-Life Depression. *JAMA Psychiatry*
- 1024 (2022) doi:10.1001/jamapsychiatry.2022.0020.
- 1025 76. Yang, J., Lee, S. H., Wray, N. R., Goddard, M. E. & Visscher, P. M. GCTA-GREML
- accounts for linkage disequilibrium when estimating genetic variance from genome-wide
- 1027 SNPs. *PNAS* **113**, E4579–E4580 (2016).
- 1028 77. Purcell, S. et al. PLINK: A Tool Set for Whole-Genome Association and Population-Based
- 1029 Linkage Analyses. *Am J Hum Genet* **81**, 559–575 (2007).
- 1030 78. Magno, R. & Maia, A.-T. gwasrapidd: an R package to query, download and wrangle
- 1031 GWAS catalog data. *Bioinformatics* **36**, 649–650 (2020).

1032 79. Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for 1033 interpreting genome-wide expression profiles. Proceedings of the National Academy of 1034 Sciences 102, 15545-15550 (2005). 1035 80. Kuhn, H. W. The Hungarian method for the assignment problem. Naval Research Logistics 1036 Quarterly 2, 83–97 (1955). 1037 Stasinopoulos, D. M. & Rigby, R. A. Generalized Additive Models for Location Scale and 1038 Shape (GAMLSS) in R. Journal of Statistical Software 23, 1–46 (2008). 1039 82. Klein, A. & Tourville, J. 101 Labeled Brain Images and a Consistent Human Cortical 1040 Labeling Protocol. Frontiers in Neuroscience 6, 171 (2012). 1041 83. Nadeau, C. & Bengio, Y. Inference for the Generalization Error. in Advances in Neural 1042 Information Processing Systems 12 (eds. Solla, S. A., Leen, T. K. & Müller, K.) 307–313 1043 (MIT Press, 2000). 1044

1046

1047

1048

1049

1050

1051

1052

1053

1054

1055

1056

1057

1058

1059

1060

1061

1062

1063

1064

1065

1066

1067

Acknowledgments The iSTAGING consortium is a multi-institutional effort funded by NIA by RF1 AG054409. The Baltimore Longitudinal Study of Aging neuroimaging study is funded by the Intramural Research Program, National Institute on Aging, National Institutes of Health and by HHSN271201600059C. The BIOCARD study is in part supported by NIH grant U19-AG033655. The PHENOM study is funded by NIA grant R01MH112070 and by the PRONIA project as funded by the European Union 7th Framework Program grant 602152. Other supporting funds are 5U01AG068057, 1U24AG074855, and S10OD023495. Data were provided [in part] by OASIS OASIS-3: Principal Investigators: T. Benzinger, D. Marcus, J. Morris; NIH P50 AG00561, P30 NS09857781, P01 AG026276, P01 AG003991, R01 AG043434, UL1 TR000448, R01 EB009352. AV-45 doses were provided by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly. OC has received funding from the French government under management of Agence Nationale de la Recherche as part of the "Investissements d'avenir" program, reference ANR-19-P3IA-0001 (PRAIRIE 3IA Institute) and reference ANR-10-IAIHU-06 (Agence Nationale de la Recherche-10-IA Institut Hospitalo-Universitaire-6). This research has been conducted using the UK Biobank Resource under Application Number 35148. Data used in preparation of this article were in part obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wpcontent/uploads/how to apply/ADNI Acknowledgement List.pdf. ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging

1069

1070

1071

1072

1073

1074

1075

1076

1077

1078

1079

1080

1081

1082

1083

1084

1085

and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Dr. Wen and Dr. Davatzikos had full access to all the data in the study. They took responsibility for the integrity of the data and the accuracy of the data analysis.

Novel genomic loci influence patterns of structural covariance in the human brain

- Junhao Wen^{1,2*}, Ilya M. Nasrallah^{2,3}, Ahmed Abdulkadir², Theodore D. Satterthwaite^{2,4}, Zhijian Yang²,
- Guray Erus², Timothy Robert-Fitzgerald⁵, Ashish Singh², Aristeidis Sotiras⁶, Aleix Boquet-Pujadas⁷,
- 1091 Elizabeth Mamourian², Jimit Doshi², Yuhan Cui², Dhivya Srinivasan², Ioanna Skampardoni², Jiong
- 1092 Chen², Gyujoon Hwang², Mark Bergman², Jingxuan Bao⁸, Yogasudha Veturi⁹, Zhen Zhou², Shu Yang⁸,
- Paola Dazzan¹⁰, Rene S. Kahn¹¹, Hugo G. Schnack¹², Marcus V. Zanetti¹³, Eva Meisenzahl¹⁴, Geraldo F.
- Busatto¹³, Benedicto Crespo-Facorro¹⁵, Christos Pantelis¹⁶, Stephen J. Wood¹⁷, Chuanjun Zhuo¹⁸, Russell
- T. Shinohara^{2,5}, Ruben C. Gur⁴, Raquel E. Gur⁴, Nikolaos Koutsouleris¹⁹, Daniel H. Wolf^{2,4}, Andrew J.
- Saykin²⁰, Marylyn D. Ritchie⁹, Li Shen⁸, Paul M. Thompson²¹, Olivier Colliot²², Katharina Wittfeld²³,
- Hans J. Grabe²³, Duygu Tosun²⁴, Murat Bilgel²⁵, Yang An²⁵, Daniel S. Marcus²⁶, Pamela LaMontagne²⁶,
- Susan R. Heckbert²⁷, Thomas R. Austin²⁷, Lenore J. Launer²⁸, Mark Espeland²⁹, Colin L Masters³⁰, Paul
- 1099 Maruff³⁰, Jurgen Fripp³¹, Sterling C. Johnson³², John C. Morris³³, Marilyn S. Albert³⁴, R. Nick Bryan³,
- Susan M. Resnick²⁵, Yong Fan², Mohamad Habes³⁵, David Wolk^{2,36}, Haochang Shou^{2,5}, and Christos
- Davatzikos^{2*}, for the iSTAGING, the BLSA, the BIOCARD, the PHENOM, the ADNI studies, and the
- 1102 AI4AD consortium

1086

1087 1088

- 1104 Laboratory of AI and Biomedical Science (LABS), Stevens Neuroimaging and Informatics Institute, Keck School of
- 1105 Medicine of USC, University of Southern California, Los Angeles, California, USA.
- 1106 ²Artificial Intelligence in Biomedical Imaging Laboratory (AIBIL), Center for Biomedical Image Computing and
- Analytics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
- 1108 ³Department of Radiology, University of Pennsylvania, Philadelphia, USA.
- ⁴Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
- ⁵Penn Statistics in Imaging and Visualization Center, Department of Biostatistics, Epidemiology, and Informatics,
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
- 1112 ⁶Department of Radiology and Institute for Informatics, Washington University School of Medicine, St. Louis, USA
- ⁷Biomedical Imaging Group, EPFL, Lausanne, Switzerland
- 1114 8Department of Biostatistics, Epidemiology and Informatics University of Pennsylvania Perelman School of Medicine,
- 1115 Philadelphia, USA
- 1116 ⁹Department of Genetics and Institute for Biomedical Informatics, Perelman School of Medicine, University of
- 1117 Pennsylvania, Philadelphia, PA, USA
- 1118 ¹⁰Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College
- 1119 London, London, UK
- 1120 ¹¹Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, USA
- 1121 ¹²Department of Psychiatry, University Medical Center Utrecht, Utrecht, Netherlands
- 1122 ¹³Institute of Psychiatry, Faculty of Medicine, University of São Paulo, São Paulo, Brazil
- 1123 ¹⁴ Department of Psychiatry and Psychotherapy, HHU Düsseldorf, Germany
- 1124 ¹⁵Hospital Universitario Virgen del Rocio, University of Sevilla-IBIS; IDIVAL-CIBERSAM, Sevilla, Spain
- 1125 ¹⁶Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health,
- 1126 Carlton South, Australia
- 1127 ¹⁷Orygen and the Centre for Youth Mental Health, University of Melbourne; and the School of Psychology,
- 1128 University of Birmingham, UK
- 1129 ¹⁸key Laboratory of Real Tine Tracing of Brain Circuits in Psychiatry and Neurology (RTBCPN-Lab), Nankai
- 1130 University Affiliated Tianjin Fourth Center Hospital; Department of Psychiatry, Tianjin Medical University, Tianjin,
- 1131 China
- 1132 ¹⁹Department of Psychiatry and Psychotherapy, Ludwig-Maximilian University, Munich, Germany
- 1133 ²⁰Radiology and Imaging Sciences, Center for Neuroimaging, Department of Radiology and Imaging Sciences,
- 1134 Indiana Alzheimer's Disease Research Center and the Melvin and Bren Simon Cancer Center, Indiana University
- 1135 School of Medicine, Indianapolis
- 1136 ²¹Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of
- 1137 Medicine of USC, University of Southern California, Marina del Rey, California

- 1138 ²²Sorbonne Université, Institut du Cerveau Paris Brain Institute ICM, CNRS, Inria, Inserm, AP-HP, Hôpital de la
- 1139 Pitié Salpêtrière, F-75013, Paris, France
- 1140 ²³Department of Psychiatry and Psychotherapy, German Center for Neurodegenerative Diseases (DZNE), University
- 1141 Medicine Greifswald, Germany
- 1142 ²⁴Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA
- 1143 ²⁵Laboratory of Behavioral Neuroscience, National Institute on Aging, NIH, USA
- 1144 ²⁶Department of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA
- 1145 ²⁷Cardiovascular Health Research Unit and Department of Epidemiology, University of Washington, Seattle, WA, USA
- 1147 ²⁸Neuroepidemiology Section, Intramural Research Program, National Institute on Aging, Bethesda, Maryland, USA
- 1148 ²⁹Sticht Center for Healthy Aging and Alzheimer's Prevention, Wake Forest School of Medicine, Winston-Salem,
- North Carolina, USA
- 1150 ³⁰Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
- 1151 ³¹CSIRO Health and Biosecurity, Australian e-Health Research Centre CSIRO, Brisbane, Queensland, Australia
- 1152 ³²Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
- 1154 ³³Knight Alzheimer Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA
- 1155 ³⁴Department of Neurology, Johns Hopkins University School of Medicine, USA
- 35Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at
 San Antonio, San Antonio, USA
- 1158 ³⁶Department of Neurology and Penn Memory Center, University of Pennsylvania, Philadelphia, USA
- 1160 *Corresponding authors:

- 1161 Junhao Wen, Ph.D. <u>junhaowe@usc.edu</u>
- 2025 Zonal Ave, Los Angeles, CA 90033, United States
- 1163 Christos Davatzikos, Ph.D. Christos. Davatzikos@pennmedicine.upenn.edu
- 1164 3700 Hamilton Walk, 7th Floor, Philadelphia, PA 19104, United States

1166 eMethod 1: Empirical validation of sopNMF 1167 eMethod 2: Reproducibility index 1168 eMethod 3: Inter-site image harmonization 1169 eMethod 4: Quality check of the image processing pipeline 1170 eMethod 5 Definition of the index, candidate, independent significant, and SNP and 1171 genomic locus 1172 eMethod 6 Cross-validation procedure for PAML 1173 eFigure 1: Comparison between opNMF and sopNMF 1174 eFigure 2: Reproducibility of the sopNMF brain parcellation eFigure 3: Scatter plot for the h^2 estimates from the discovery and replication sets 1175 1176 eFigure 4: Sensitivity check for the GWAS results using the discovery set in UKBB eFigure 5: Machine learning performance for disease classification and age prediction 1177 1178 eFigure 6: Annotation of MUSE PSCs to MuSIC PSCs based on the overlap index 1179 eFigure 7: Summary statistics of the multi-scale PSCs of MuSIC 1180 eTable 1: Study cohort characteristics 1181 eTable 2: Clinical phenotypes and diagnoses used in machine learning classification eTable 3: Comparison of variants identified via MuSIC with other studies 1182 1183 eTable 4: Classification balanced accuracy for disease classification and effect size of these imaging signatures 1184 1185 eTable 5: 119 MUSE gray matter regions of interest 1186 eAlgorithm 1: Algorithm for sopNMF

1189

1190

1191

1192

1193

1194

1195

1196

1197

1198

1199

1200

1201

1202

1203

1204

1205

1206

1207

1208

eMethod 1: Empirical validation of sopNMF. For the empirical validation of sopNMF, the comparison population (**Method 1** in the main manuscript) was used so that the machine's memory could be sufficient to read the entire data for opNMF. For sopNMF, different choices of batch size (i.e., BS=32, 64, 128, and 256) were tested. We hypothesized that sopNMF could approximate the optima of opNMF during optimization, i.e., resulting in similar parts-based representation, training loss, and sparsity. TensorboardX was embedded into the sopNMF framework to monitor the training process dynamically. All experiments were performed on an Ubuntu machine with a maximum RAM of 32 GB and 8 CPUs. The predefined maximum number of epochs for all experiments is 50,000, and the tolerance of early stopping criteria is 100 epochs based on the training loss. We qualitatively compared the extracted PSCs and quantitatively for the training loss, the sparsity of the component matrix W, and the memory consumption for C=20 (number of PSCs). The 20 PSCs were spatially consistent between opNMF and sopNMF, despite that some regions were decomposed into different PSCs (i.e., the white ellipse in **eFig. 1A**). For the training loss, opNMF obtained the lowest loss (1.103 x 10^6), and the loss of sopNMF were 1.107 x 10^6 , 1.108 $x10^6$, 1.111 $x10^6$ and 1.210 $x10^6$ for BS =256, 128, 64, and 32, respectively (**eFig. 1D**). For the sparsity of the component matrix, all models obtained comparable results (sparsity ≈ 0.83 , eFig. **1E**). The estimated memory consumptions during the training process were 28.65, 4.02, 3.81, 2.60, 1.47 GB for opNMF and sopNMF (BS =256, 128, 64, and 32), respectively (Fig. e1F).

eMethod 2: Reproducibility index.
We proposed a reproducibility index (RI) to test the reproducibility of sopNMF for brain parcellation:
We used the Hungarian match algorithm⁸⁰ to match the pairs of PSCs between two splits under the specific condition that maximizes the similarity (i.e., minimizes the cost of workers/jobs in its original formulation).
For each pair of PSCs, we calculated the inner product of the vectors (R^d), referred to as RI. This index takes values between [0, 1], with higher values indicating higher reproducibility.
For each scale C, we presented the mean/standard deviation of the RIs for all PSCs.

eMethod 3: Inter-site image harmonization

We used an extensively validated statistical harmonization approach, i.e., ComBat-GAM, ¹² to harmonize the extracted multi-scale PSCs. This method estimates the variability in volumetric measures due to differences in site/cohort-specific imaging protocols based on variances observed within and across control groups while preserving normal variances due to age, sex, and intracranial volume (ICV) differences. The model was initially trained on the discovery set and then applied to the replication set.

eMethod 4: Quality check of the image processing pipeline.

Raw T1-weighted MRIs were first quality checked (QC) for motion, image artifacts, or restricted field-of-view. Another QC was performed: First, the images were examined by manually evaluating for pipeline failures (e.g., poor brain extraction, tissue segmentation, and registration errors). Furthermore, a second step automatically flagged images based on outlying values of quantified metrics (i.e., PSC values); those flagged images were re-evaluated.

1238

1239

1240

1241

1242

1243

1244

1245

1246

1247

1248

1249

1250

1251


1252

1253


eMethod 5: Definition of the index, candidate, independent significant, and lead SNP and genomic locus. Index SNP They are defined as SNPs with a p-value threshold \leq 5e-8 (*clump-p1*) from GWAS summary statistics. Independent significant SNP They are defined as the index SNPs, which are independent of each other (not in linkage disequilibrium) with $r^2 \le 0.6$ (clump-r2) within 250 kilobases (non-overlapping, clump-kb) away from each other. Lead SNP and genomic loci They are defined as the independent significant SNPs, which are independent of each other with a more stringent $r^2 < 0.1$ (clump-r2) within 250 kilobases (non-overlapping, clump-kb) away from each other. Each of these clumps is defined as a *genomic locus*. Candidate SNP With each genomic locus, candidate SNPs are defined as the SNPs whose association p-values are smaller than 0.05 (clump-p2). The definitions followed instructions from FUMA²⁶ and Plink⁷⁷ software.

eMethod 6: Cross-validation procedure for PAML.


Nested cross-validation was adopted for all tasks following the good-practice guidelines proposed in our previous works^{36,37,53}. In particular, an outer loop was used to evaluate the task performance (250 repetitions of random hold-out splits with 80% of data for training). In contrast, an inner loop focused on tuning the hyperparameters (10-fold splits). We computed the balanced accuracy (BA) to evaluate the classification tasks. We calculated the effect size (Cohen's *d*) and p-value for each SPARE index to quantify its discriminative power.




eFigure 1: Comparison between opNMF and sopNMF. (**A**) Qualitative evaluation: The extracted components are shown in the original image space, with each PSC displayed in a distinct color. The white ellipse indicates the region where the models diverge. Quantitative evaluation: training loss (**B**, **D**) and sparsity (**C**, **E**) demonstrated similar patterns between models, except that batch size (BS) = 32 had a larger loss than the other models. Comparing the estimated memory consumption during training across models shows significant advantages for all sopNMF models compared to opNMF.



eFigure 2: Reproducibility of the sopNMF brain parcellation. In general, sopNMF demonstrated high reproducibility under various conditions. For each brain PSC, the reproducibility index (RI) was calculated (**Supplementary eMethod 2**). (**A**) Split-sample analyses, where the training population (*N*=4000) was randomly split into two halves while maintaining similar age, sex, and site distribution between groups. (**B**) Split-sex analyses, where the training population was divided into males and females. Colored PSCs on the brain template illustrate the same PSC independently derived from the two splits. (**C**) Leave-one-site-out analyses for C32 PSCs., where the training populations excluding participants from each site (BIOCARD, ADNI, WARP, AIBL, ABIDE, BLSA, OASIS, CARDIA, PHENOM, PENN, UKBB, and WHIMS) were independently trained with sopNMF. The RI indices were compared to the sopNMF results using the full training sample (N=4000).



eFigure 3: Scatter plot for the h^2 estimates from the discovery and replication sets. The SNP-based heritability was estimated independently for the discovery set (N=18,052) and replication set (N=15,243). In particular, the two estimates were highly correlated (r=0.94, p-value $< 10^{-6}$), demonstrating a highly similar genetic architecture across different sets of UKBB data.




eFigure 4: Sensitivity check for the GWAS results using the discovery set in UKBB. A) The GWAS results for participants with European ancestry in the discovery set. **B)** The GWAS results for participants with European ancestry in the discovery and replication sets. **C)** The GWAS results for participants with all different ancestries in the discovery set. **D)** The GWAS


1293

1294

results for participants with European ancestry in the discovery set by adding four additional imaging-related covariates. **E**) The GWAS results for participants with non-European ancestry in the discovery set. **F**) The GWAS results for participants with the independent ADNI WGS data.




eFigure 5: Machine learning performance for disease classification. Balanced accuracy (BA) for each classification task using different features from multi-scale MuSIC, AAL, and RAVENS (higher score better). Details are presented in **eTable 4**.



eFigure 6: Annotation of MUSE ROIs to MuSIC PSCs based on the overlap index. We automatically annotated the 119 MUSE GM PSCs to the MuSIC atlases at all six scales (*C*=32, 64, 128, 256, 512, and 1024). To this end, we calculated an overlap index (OI) to quantify the spatial overlaps between MUSE and MuSIC. For instance, for each MUSE PSC (**eTable 5**) vs. each of the 32 PSCs of MuSIC at *C*=32 scale, the OI equals the proportion of the number of overlap voxels and the total number of voxels in the MUSE PSC. Here we illustrate by mapping the right thalamus of MUSE to all 6 MuSIC atlases. The highest OIs are 0.82, 0.70, 0.86, 0.30, 0.09, 0.05 for C32_1, C64_42, C128_114, C256_110, C512_249, and C1024_249 PSCs. This functionality is available in BRIDGEPORT:

https://www.cbica.upenn.edu/bridgeport/MUSE/Right%20Thalamus%20Proper



eFigure 7: Summary statistics of the multi-scale PSCs of MuSIC. Multi-scale PSCs show considerable normal distributions, i.e., symmetrical distribution (**A**) with a low kurtosis (**B**). Moreover, we fit the Generalized Additive Model for Location, Scale, and Shape (GAMLSS)⁸¹ model (fractional polynomials with 2 degrees) to each PSC to delineate the age trajectory over the lifespan in males (solid lines) and females (dotted lines), respectively (**C**). For visualization

purposes, we selectively display the first 10 PSCs from each scale of the MuSIC atlases. In general, males have larger brain volumes than females. For **D-F**, we selectively showed the distribution of age (**D**) and the distribution of PSC volume before harmonization (**E**) and after harmonization (**F**) for C32_1 within each site in the discovery set. For **G** and **H**, we tested the normality of the PSC volume (C32_1) from each pair of sites using the Shapiro-Wilk test (*scipy.stats.shapiro* function) in the discovery set before (**G**) harmonization and after harmonization (**H**). A higher -log₁₀(P) indicates the data are less likely to be normally distributed. As a general trend, our statistical harmonization techniques demonstrated a slight improvement in the normality of the data. Additionally, we consistently applied normality transformations to all statistical analyses, including GWAS, to mitigate any non-normality.

eTable 1. Study cohort characteristics.

The current study consists of two main populations/sets: the discovery set (N=32,440, including participants from the first download of the UKBB data) and the replication set (N=18,259, the second download of the UKBB data). To train the sopNMF model for MuSIC, we selected 250 patients (PT) and 250 healthy controls (CN) for each decade of the discovery set, resulting in 4000 participants in total, referred to as the training population. Age ranges from 5 to 97 years and is shown with mean and standard deviation. Sex is displayed with the number and percentage of female participants. Data was collected from 12 studies, 130 sites, and 12 countries. The number of sites (country) per study is detailed as follows:

- ADNI: 63 sites (USA)
- UKBB: 5 sites (UK)
- AIBL: 2 sites (Australia)
- BIOCARD: 2 sites (USA)
- BLSA: 1 site (USA)
 - CARDIA: 3 sites (USA)
- OASIS: 1 site (USA)
 - PENN: 1 site (USA)
 - WHIMS: 14 sites (USA)
 - WRAP 1 site (USA)
 - PHENOM: 12 sites (China, Brazil, Australia, Germany, Spain, USA, Netherlands)
 - ABIDE: 25 sites (USA, Netherlands, Belgium, Germany, Ireland, Switzerland, France)

Abbreviations: CN: healthy control; AD: Alzheimer's disease; MCI: mild cognitive impairment; SCZ: schizophrenia; ASD: autism spectrum disorder; MDD: major depressive disorder; DM:

diabetes; HTN: hypertension.

^aUKBB data were separately downloaded two times: the first was the N=21,305 in the discovery set, and the second was the replication set.

^bWe define CN (healthy controls) as participants that do not have any of the diseases listed here. These CN participants might have diagnoses of other illnesses or comorbidities (e.g., participants from UKBB have a wide range of pathology based on ICD-10).

Study	N (50,699)	Age (5-97 year)	Sex (female/%	CN ^b	AD	MCI	SCZ	ASD	MDD	DM	HTN
Discovery set	32,440	60.04± 14.87	16,868/52	24,98 0	954	1288	1094	597	1476	1093	958
ADNI	1765	73.66± 7.19	798/45	297	343	875	NA	NA	NA	NA	250
UKBB ^a	21,305	62.58± 7.48	10,101/53	18,73 5	1	NA	NA	NA	1476	1093	NA
AIBL	830	71.36± 6.78	471/57	625	86	115	NA	NA	NA	NA	4
BIOCARD	288	58.15± 10.54	115/60	283	1	4	NA	NA	NA	NA	NA
BLSA	1114	65.44± 14.11	589/53	729	9	11	NA	NA	NA	NA	365
CARDIA	892	51.21± 3.98	471/53	620	NA	NA	NA	NA	NA	NA	272
OASIS	983	69.92± 9.75	557/57	759	220	NA	NA	NA	NA	NA	4

PENN	807	72.63± 10.65	333/59	173	294	283	NA	NA	NA	NA	57
WHIMS	995	69.61± 3.64	995/100	986	NA	NA	NA	NA	NA	NA	6
WRAP	116	63.36± 6.06	79/68	116	NA	NA	NA	NA	NA	NA	NA
PHENOM	2125	30.21± 10.60	854/40	1031	NA	NA	1094	NA	NA	NA	NA
ABIDE	1220	17.92 <u>±</u> 9.01	203/17	623	NA	NA	NA	597	NA	NA	NA
Replication set ^a	18,259	54.70± 7.43	9742/53	NA	NA	NA	NA	NA	NA	NA	NA

eTable 2: Clinical phenotypes and diagnoses used in machine learning classification.

We harmonized the population of the phenotypes of interest per study definitions:

- We combined AD and MCI patients from ADNI, PENN, and AIBL but excluded OASIS subjects because of the different diagnostic criteria of an AD patient in OASIS.
- For several binary disease phenotypes, we used the ICD-10 diagnosis (https://biobank.ndph.ox.ac.uk/ukb/field.cgi?id=41270). Note that ICD-10 diagnoses are generally collected from the participants' medical inpatient records. We first included diseases from the following categories:
 - O Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D-XXX, XXX represents the ID of a specific disease);
 - o Endocrine, nutritional, and metabolic diseases (E-XXX);
 - o Mental and behavioral disorders (F-XXX);
 - o Diseases of the nervous system (G-XXX);
 - o Diseases of the circulatory system (I-XXX).

We then set a threshold of 75 patients for any ICD-10 diagnosis. We finally randomly selected age and sex-matched healthy controls (excluding all patients in all diagnoses). ^a: For major depressive disorder, we used the inclusion criteria from our previous work. ⁷⁵

• For cognitive scores, we included:

1365

1366

1367

1368

1369

1370

1371

13721373

1374

1375

1376

1377

1378

1379

1380

1381 1382

1383

1384

1385 1386

1387

1388 1389

1390

1391 1392

1393

1394

1395

1396

1397

- o Tower rearranging (https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=21004)
- o Matrix pattern (https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=6373)
- o TMT-A (https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=6348)
- o TMT-B (https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=6350)
- o DSST (https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=23324)
- o Pairs matching (https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=399)
- o Numerical memory (https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=4282)
- o Prospective memory (https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=4288)
- o Reaction time (https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=20023)
- o Fluid intelligence (https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=20016)

AD: Alzheimer's disease; MCI: mild cognitive impairment; SCZ: schizophrenia; DM: diabetes mellitus; MDD: major depressive disorder; HTN: hypertension; ASD: autism spectrum disorder; CN: healthy control; PT: patient; *N*: number of participants. We decided not to harmonize cognitive scores from different studies.

Trait (ICD-10 code or ID)	Sample size (CN/PT or <i>N</i>)	Site	Trait (ICD-10 code or ID)	Sample size (CN/PT or <i>N</i>)	Site
AD	1095/723	ADNI, PENN, & AIBL	Carpal tunnel syndrome (G560)	901/901	UKBB
MCI	1273/1095	ADNI, PENN, & AIBL	Lesion of ulnar nerve (G562)	104/104	UKBB
SCZ	1031/1094	PHENOM	Lesion of plantar nerve (G576)	163/163	UKBB
DM	1093/1093	UKBB	Angina pectoris (I20)	1535/1535	UKBB
$\mathrm{MDD^a}$	1476/1476	UKBB	Acute myocardial infarction (I21)	769/769	UKBB
HTN	934/887	ADNI, BLSA & CARDIA	Chronic ischaemic heart disease (I25)	2217/2217	UKBB

ASD	623/597	ABIDE	Pulmonary embolism (I20)	351/351	UKBB
Iron deficiency	1012/1012	UKBB	Cardiomyopathy (I42)	116/116	UKBB
anemia (D50) Vitamin B12 deficiency anemia (D50)	78/78	UKBB	Paroxysmal tachycardia (I47)	320/320	UKBB
Agranulocytosis (D70)	245/245	UKBB	Heart failure (I50)	436/436	UKBB
Thyrotoxicosis (E05)	205/205	UKBB	Cerebral infarction (I63)	291/291	UKBB
Vitamin D deficiency (E55)	180/180	UKBB	Vitamin B deficiency (E53)	130/130	UKBB
Obesity (E66)	1481/1481	UKBB	Hemiplegia (G81)	111/111	UKBB
Lipoprotein metabolism disorder (E78)	3880/3880	UKBB	Facial nerve disorders (G51)	95/95	UKBB
Mineral metabolism disorder (E83)	291/291	UKBB	Tower rearranging (21004)	8412	UKBB
Volume depletion	240/240	UKBB	Matrix pattern (6373)	8501	UKBB
Delirium	92/92	UKBB	TMT-A (6348)	8599	UKBB
Alcohol abuse	341/341	UKBB	TMT-B (6350)	8599	UKBB
Tobacco abuse	863/863	UKBB	DSST (23324)	8523	UKBB
Bipolar affective disorder	77/77	UKBB	Pairs matching (399)	20945	UKBB
Phobic anxiety disorder	84/84	UKBB	Numerical memory (4282)	9323	UKBB
Multiple sclerosis	109/109	UKBB	Prospective memory (4288)	19681	UKBB
Epilepsy	250/250	UKBB	Reaction time (20023)	21258	UKBB
Migraine	508/508	UKBB	Fluid intelligence (20016)	19184	UKBB
Sleep disorders	590/590	UKBB			

 eTable 3: Comparison of variants identified via MuSIC with other studies. Using the AAL atlas, we found (using the same data in the current study) that 269 independent significant SNPs had 356 pairwise associations with 54 AAL brain regions. 230 out of the 269 SNPs matched with the SNPs in MuSIC. Among the 39 unmatched SNPs, 15 SNPs were in linkage disequilibrium (LD, $r^2 > 0.6$) with MuSIC SNPs (**Supplementary eFile 5**). As a second example, Zhao et al.⁴ reported that 251 independent significant SNPs had 346 pairwise associations with 43 GM regions using the Mindboggle atlas on the UKBB (N=19,629). ⁸² 129 of the 251 SNPs matched with SNPs identified by MuSIC. Among these non-matching SNPs (127), 31 were in LD with MuSIC SNPs (**Supplementary eFile 6**). Similarly, Elliot et al.⁵ (N=8428) discovered that 20 independent significant SNPs had 58 pairwise associations with 52 GM regions from atlases in Freesurfer and FSL software. Out of the 20 SNPs, 16 coincided with MuSIC SNPs. Among the four unmatched SNPs, 1 SNP was in LD with MuSIC SNPs (**Supplementary eFile 7**). Note that the definition of independent significant SNPs or genomic loci might slightly differ between studies.

Study/Atlas	Identified genomic loci	Matched loci	Loci in LD	Novel loci	Database	Sample size	Ancestry
MuSIC	915	NA	NA	NA	UKBB	18,052	European
AAL	218	162	13	740	UKBB	18,052	European
Zhao et al.4	251	73	14	828	UKBB	19,629	European
Elliot et al. ⁵	20	16	1	898	UKBB	8428	European
GWAS Catalog	NA	298	NA	617	NA	NA	NA

eTable 4: Classification balanced accuracy for disease classification and effect size of these imaging signatures.

Disease classification performance is presented using balanced accuracy. The mean and standard deviation are presented. Cohen's *d* was computed to compare the SPARE scores between groups. Multi-scale classification^a: All 2003 PSCs from multiple scales were fit into the classifier. Multi-scale classification^b: PSCs from all scales were fit into the classifier with a nested feature selection procedure (SVM-REF). The motivation is that PSCs from different scales are hierarchical and correlated. The nested feature selection can select the features most relevant to the specific task. We avoided any statistical comparison of the performance of machine learning models because available statistical tests are liberal and often lead to false-positive conclusions due to the complexity of the cross-validation procedure.⁸³

a): Classification results for all subjects in all sites using a nested CV procedure

a). Classii	dy. Classification results for all subjects in all sites using a nested expresedate													
PSC	AD	d	MCI	d	SCZ	d	DM	d	HTN	d	MDD	d	ASD	d
C32	0.78± 0.02	1.52	0.62± 0.02	0.59	0.55± 0.02	0.30	0.56± 0.02	0.35	0.55± 0.02	0.28	0.52± 0.02	0.16	0.50± 0.02	0.07
C64	0.81 ± 0.02	1.73	0.63± 0.02	0.66	0.57 ± 0.02	0.41	0.57 ± 0.02	0.40	0.56± 0.02	0.31	0.53 ± 0.02	0.17	0.53± 0.02	0.19
C128	0.82 ± 0.02	1.82	0.65 ± 0.02	0.76	0.59± 0.02	0.47	0.56± 0.02	0.33	0.55 ± 0.02	0.30	0.52± 0.02	0.15	0.52± 0.02	0.15
C256	0.85± 0.02	2.08	0.66± 0.02	0.91	0.59± 0.02	0.50	0.56± 0.02	0.47	0.54± 0.02	0.31	0.51± 0.02	0.13	0.52± 0.02	0.16
C512	0.88 ± 0.02	2.34	0.67± 0.02	1.06	0.62± 0.02	0.62	0.57 ± 0.02	0.54	0.56± 0.02	0.42	0.52± 0.02	0.05	0.54± 0.02	0.24
C1024	0.90± 0.02	2.50	0.72± 0.02	1.12	0.65± 0.02	0.75	0.60± 0.02	0.59	0.59± 0.02	0.46	0.56± 0.02	0.13	0.55± 0.02	0.29
Multi- scale ^a	0.91± 0.02	2.54	0.72± 0.02	1.12	0.66± 0.02	0.77	0.61 ± 0.02	0.64	0.59± 0.02	0.47	0.55 ± 0.02	0.23	0.56± 0.02	0.30
Multi- scale ^b	0.92± 0.02	2.61	0.73± 0.02	1.13	0.67 ± 0.02	0.78	0.64± 0.02	0.67	0.61 ± 0.02	0.49	0.55 ± 0.02	0.26	0.58± 0.02	0.32
AAL	0.82 ± 0.02	1.81	0.66 ± 0.02	0.75	0.59± 0.02	0.46	0.57± 0.02	0.32	0.57 ± 0.02	0.35	0.52 ± 0.02	0.08	0.52± 0.02	0.14
RAVENS	0.85± 0.02	2.04	0.64 ±0.02	0.74	0.60± 0.02	0.45	0.58± 0.02	0.33	0.55± 0.02	0.34	0.50± 0.02	0.05	0.54± 0.02	0.15

b): The classification results of the balanced accuracy (BA) from the test data in the nested CV and the independently left-out site for the task of AD vs. CN were assessed using all available multi-scale PSCs^a. Three sites, namely ADNI, AIBL, and PENN, were considered for this analysis. However, UKBB, BIOCARD, and BLSA data were excluded due to limited AD cases (eTable 1). Similarly, data from OASIS were excluded due to discrepancies in the diagnosis criteria for AD, as previously stated in our previous work³⁶.

Left-out site	Test BA in CV	Test BA in the left-out site
ADNI	0.90±0.02	0.88±0.02
AIBL	0.88±0.02	0.95±0.02
PENN	0.90+0.02	0.95+0.02

eTable 5: 119 MUSE gray matter regions of interest.

1435

1436

1437

L: Left hemisphere; R: Right hemisphere; ROI: region of interest.

ht hemisphere; ROI: region of interest.	
MUSE ROI	MUSE ROI
Occipital fusiform gyrus (R)	Anterior insula (L)
Planum temporale (R)	Anterior orbital gyrus (R)
Cerebellar vermal lobules I-V	Anterior orbital gyrus (L)
Cerebellar vermal lobules VI-VII	Angular gyrus (R)
Cerebellar vermal lobules VIII-X	Angular gyrus (L)
Basal forebrain (R)	Calcarine cortex (R)
Basal forebrain (L)	Calcarine cortex (L)
Middle temporal gyrus (L)	Central operculum (R)
Occipital pole (R)	Central operculum (L)
Planum temporale (L)	Cuneus (R)
Parietal operculum (L)	Cuneus (L)
Postcentral gyrus (R)	Entorhinal area (R)
Postcentral gyrus (L)	Entorhinal area (L)
Posterior orbital gyrus (R)	Frontal operculum (R)
Temporal pole (R)	Frontal operculum (L)
Temporal pole (L)	Frontal pole (R)
Triangular part of the inferior frontal gyrus	
(R)	Frontal pole (L)
Triangular part of the inferior frontal gyrus	
(L)	Fusiform gyrus (R)
Transverse temporal gyrus (R)	Fusiform gyrus (L)
	Gyrus rectus (R)
	Gyrus rectus (L)
	Inferior occipital gyrus (R)
	Inferior occipital gyrus (L)
	Inferior temporal gyrus (R)
	Inferior temporal gyrus (L)
	Subcallosal area (R)
	Subcallosal area (L)
	Superior frontal gyrus (R)
	Superior frontal gyrus (L)
	Supplementary motor cortex (R)
	Supplementary motor cortex (L)
	Supramarginal gyrus (R)
* *	Supramarginal gyrus (L)
	Superior occipital gyrus (R)
	Superior occipital gyrus (L)
	Superior parietal lobule (R)
	Superior parietal lobule (L)
* *	Superior temporal gyrus (R)
Parietal operculum (R)	Superior temporal gyrus (L)
5	
Posterior orbital gyrus (I)	
	Occipital fusiform gyrus (R) Planum temporale (R) Cerebellar vermal lobules I-V Cerebellar vermal lobules VI-VII Cerebellar vermal lobules VIII-X Basal forebrain (R) Basal forebrain (L) Middle temporal gyrus (L) Occipital pole (R) Planum temporale (L) Parietal operculum (L) Postcentral gyrus (R) Postcentral gyrus (R) Posterior orbital gyrus (R) Temporal pole (R) Temporal pole (L) Triangular part of the inferior frontal gyrus (R) Triangular part of the inferior frontal gyrus (L)

eAlgorithm 1: Algorithm for sopNMF.

The source code of the Python implementation of sopNMF is available here:

https://github.com/anbai106/SOPNMF

Algorithm 1: sopNMF

1438

1439

1440

1441 1442 1443 • **Input:**maximum number of epochs e, number of component C or r, batch size b, early stopping criteria θ (i.e., the loss without decreasing for a certain epochs) ;

```
• Output:W \in \mathbb{R}^{d \times r}, H \in \mathbb{R}^{r \times n};
• Initialization: W:
if not \theta or epoch \neq e then
      for p \leftarrow 0 to e do
            for i \leftarrow 0 to t do
                  Read mini-batch X_{bi}
                  Update \mathbf{W}_{i+1} via Eq. 2
            loss = \sum_{i=1}^{\left\lceil \frac{n}{b} \right\rceil} \| \boldsymbol{X}_{bi} - \boldsymbol{W} \boldsymbol{W}^T \boldsymbol{X}_{bi} \|_F^2 (Eq.3)
            if loss in \theta then
                  Stop
            else
                  Shuffle X
                   Continue
            end
      end
else
     Stop
end
```

References

- 1. Kuhn, H. W. The Hungarian method for the assignment problem. *Naval Research Logistics*
- 1447 *Quarterly* **2**, 83–97 (1955).
- 1448 2. Pomponio, R. et al. Harmonization of large MRI datasets for the analysis of brain imaging
- patterns throughout the lifespan. *Neuroimage* **208**, 116450 (2020).
- Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
- annotation of genetic associations with FUMA. *Nat Commun* **8**, 1826 (2017).
- 4. Purcell, S. et al. PLINK: A Tool Set for Whole-Genome Association and Population-Based
- 1453 Linkage Analyses. *Am J Hum Genet* **81**, 559–575 (2007).
- 1454 5. Samper-González, J. et al. Reproducible evaluation of classification methods in
- 1455 Alzheimer's disease: Framework and application to MRI and PET data. *NeuroImage* **183**,
- 1456 504–521 (2018).
- 1457 6. Wen, J. et al. Convolutional neural networks for classification of Alzheimer's disease:
- Overview and reproducible evaluation. *Medical Image Analysis* **63**, 101694 (2020).
- 1459 7. Wen, J. et al. Reproducible Evaluation of Diffusion MRI Features for Automatic
- 1460 Classification of Patients with Alzheimer's Disease. *Neuroinformatics* **19**, 57–78 (2021).
- 1461 8. Stasinopoulos, D. M. & Rigby, R. A. Generalized Additive Models for Location Scale and
- Shape (GAMLSS) in R. Journal of Statistical Software 23, 1–46 (2008).
- 1463 9. Wen, J. et al. Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical
- Symptoms, and Genetics Among Patients With Late-Life Depression. *JAMA Psychiatry*
- 1465 (2022) doi:10.1001/jamapsychiatry.2022.0020.

1466 10. Zhao, B. et al. Genome-wide association analysis of 19,629 individuals identifies variants 1467 influencing regional brain volumes and refines their genetic co-architecture with cognitive 1468 and mental health traits. *Nat Genet* **51**, 1637–1644 (2019). 1469 11. Klein, A. & Tourville, J. 101 Labeled Brain Images and a Consistent Human Cortical 1470 Labeling Protocol. Frontiers in Neuroscience 6, 171 (2012). 1471 12. Elliott, L. T. et al. Genome-wide association studies of brain imaging phenotypes in UK 1472 Biobank. Nature 562, 210-216 (2018). 1473 13. Nadeau, C. & Bengio, Y. Inference for the Generalization Error. in Advances in Neural 1474 Information Processing Systems 12 (eds. Solla, S. A., Leen, T. K. & Müller, K.) 307–313 1475 (MIT Press, 2000). 1476